GUIDELINE

Clinical practice guideline: Hoarseness (Dysphonia)

Seth R. Schwartz, MD, MPH, Seth M. Cohen, MD, MPH, Seth H. Dailey, MD, Richard M. Rosenfeld, MD, MPH, Ellen S. Deutsch, MD, M. Boyd Gillespie, MD, Evelyn Granieri, MD, MPH, MEd, Edie R. Hapner, PhD, C. Eve Kimball, MD, Helene J. Krouse, PhD, RN, ANP-BC, J. Scott McMurray, MD, Safdar Medina, MD, Karen O’Brien, MD, Daniel R. Ouellette, MD, Barbara J. Messinger-Rapport, MD, PhD, Robert J. Stachler, MD, Steven Strode, MD, MEd, MPH, Dana M. Thompson, MD, Joseph C. Stemple, PhD, J. Paul Willging, MD, Terrie Cowley, Scott McCoy, DMA, Peter G. Bernad, MD, MPH, and Milesh M. Patel, MS, Seattle, WA; Durham, NC; Madison, WI; Brooklyn, NY; Wilmington, DE; Charleston, SC; New York, NY; Atlanta, GA; Reading, PA; Detroit, MI; Uxbridge, MA; Fort Monroe, VA; Cleveland, OH; Little Rock, AR; Rochester, MN; Lexington, KY; Cincinnati, OH; Milwaukee, WI; Princeton, NJ; Washington, DC; and Alexandria, VA

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

ABSTRACT

OBJECTIVE: This guideline provides evidence-based recommendations on managing hoarseness (dysphonia), defined as a disorder characterized by altered vocal quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related quality of life (QOL). Hoarseness affects nearly one-third of the population at some point in their lives. This guideline applies to all age groups evaluated in a setting where hoarseness would be identified or managed. It is intended for all clinicians who are likely to diagnose and manage patients with hoarseness.

PURPOSE: The primary purpose of this guideline is to improve diagnostic accuracy for hoarseness (dysphonia), reduce inappropriate antibiotic use, reduce inappropriate steroid use, reduce inappropriate use of anti-reflux medications, reduce inappropriate use of radiographic imaging, and promote appropriate use of laryngoscopy, voice therapy, and surgery. In creating this guideline the American Academy of Otolaryngology—Head and Neck Surgery Foundation selected a panel representing the fields of neurology, speech-language pathology, professional voice teaching, family medicine, pulmonology, geriatric medicine, nursing, internal medicine, otolaryngology—head and neck surgery, pediatrics, and consumers.

RESULTS: The panel made strong recommendations that 1) the clinician should diagnose hoarseness (dysphonia) in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related QOL; 2) the clinician should assess the patient with hoarseness by history and/or physical examination for factors that modify management, such as one or more of the following: recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, a history of tobacco abuse, and occupation as a singer or vocal performer; 3) the clinician should diagnose hoarseness (dysphonia) in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related QOL; 4) the clinician should obtain computed tomography or magnetic resonance imaging of the patient with a primary complaint of hoarseness prior to visualizing the larynx; 5) the clinician should not prescribe anti-reflux medications for patients with hoarseness without signs or symptoms of gastroesophageal reflux disease; 6) the clinician should not routinely prescribe oral corticosteroids to treat hoarseness; 7) the clinician should visualize the larynx before prescribing voice therapy and document/communicate the results to the speech-language pathologist; and 8) the clinician should prescribe, or refer the patient to a clinician who can prescribe, botulinum toxin injections for the treatment of hoarseness caused by adductor spasmodic dysphonia. The panel offered as options that 1) the clinician may perform laryngoscopy at any time in a patient with hoarseness, or may refer the patient to a clinician who can visualize the larynx; 2) the clinician may prescribe anti-reflux medi-
cation for patients with hoarseness and signs of chronic laryngitis; and 3) the clinician may educate/counsel patients with hoarseness about control/preventive measures.

**DISCLAIMER:** This clinical practice guideline is not intended as a sole source of guidance in managing hoarseness (dysphonia). Rather, it is designed to assist clinicians by providing an evidence-based framework for decision-making strategies. The guideline is not intended to replace clinical judgment or establish a protocol for all individuals with this condition, and may not provide the only appropriate approach to diagnosing and managing this problem.

© 2009 American Academy of Otolaryngology–Head and Neck Surgery Foundation. All rights reserved.

Nearly one-third of the population has impaired voice production at some point in their lives.\(^1,2\) Hoarseness is more prevalent in certain groups, such as teachers and older adults, but all age groups and both genders can be affected.\(^1,4-6\) In addition to the impact on health and quality of life (QOL),\(^7,8\) hoarseness leads to frequent health care visits and several billion dollars in lost productivity annually from work absenteeism.\(^9\) Hoarseness is often caused by benign or self-limited conditions, but may also be the presenting symptom of a more serious or progressive condition requiring prompt diagnosis and management.

The terms hoarseness and dysphonia are often used interchangeably, although hoarseness is a symptom of altered voice quality and dysphonia is a diagnosis. Dysphonia may be broadly defined as an alteration in the production of voice that impairs social and professional communication. In contrast, hoarseness is a coarse or rough quality to the voice. Although the two terms are not synonymous, the guideline working group decided to use the term hoarseness for this guideline because it is more recognized and understood by patients, most clinicians, and the lay press.

The target patient for this guideline is anyone presenting with hoarseness (dysphonia).

- **Hoarseness (dysphonia)** is defined as a disorder characterized by altered vocal quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related QOL.
- **Impaired communication** is defined as a decreased or limited ability to interact vocally with others.
- **Reduced voice-related QOL** is defined as a self-perceived decrement in physical, emotional, social, or economic status as a result of voice-related dysfunction.

This working definition, developed by the guideline panel, assumes that hoarseness affects people differently. Some individuals may have altered voice quality, vocal effort, pitch, or loudness; others may experience problems with communication and diminished voice-related QOL.

The guideline is intended for all clinicians who are likely to diagnose and manage patients with hoarseness and applies to any setting in which hoarseness would be identified, monitored, treated, or managed. The guideline does not apply to patients with hoarseness with the following conditions: history of laryngectomy (total or partial), craniofacial anomalies, velopharyngeal insufficiency, and dysarthria (impaired articulation). However, the guideline will discuss the relevance of these conditions in managing patients with hoarseness.

There are a number of patients with modifying factors for whom many of the recommendations of the guideline may not apply. There is some discussion of these factors and how they might modify management. A partial list includes prior laryngeal surgery, recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, and patients who are singers or performers.

**GUIDELINE PURPOSE**

The primary purpose of this guideline is to improve the quality of care for patients with hoarseness based on current best evidence. Expert consensus to fill evidence gaps, when used, is explicitly stated, and is supported with a detailed evidence profile for transparency. Specific objectives of the guideline are to reduce inappropriate variations in care, produce optimal health outcomes, and minimize harm.

The guideline is intended to focus on a limited number of quality improvement opportunities, deemed most important by the working group, and is not intended to be a comprehensive, general guide for managing patients with hoarseness. In this context, the purpose is to define actions that could be taken by clinicians, regardless of discipline, to deliver quality care. Conversely, the statements in this guideline are not intended to limit or restrict care provided by clinicians based on assessment of individual patients.

While there is evidence to guide management of certain causes of hoarseness, there are currently no evidence-based clinical practice guidelines. There are variations in the use of the laser, voice therapy, steroids, and postoperative voice rest and in the treatment of reflux-related laryngitis.\(^10,11-13\) Differences in training, preference, and resource availability influence management decisions. A guideline is necessary given this practice variation and the significant public health burden of hoarseness.

This guideline addresses the identification, diagnosis, treatment, and prevention of hoarseness (dysphonia) (Table 1). In addition, it highlights needs and management options in special populations or in patients who have modifying factors. Furthermore, this guideline is intended to enhance the accurate diagnosis of hoarseness (dysphonia), promote appropriate intervention in patients with hoarseness, highlight the need for evaluation and intervention in special populations, promote appropriate therapeutic options with outcomes assessment, and improve counseling and education for prevention and management of hoarseness. This guideline may also be suitable for deriving a performance measure on hoarseness.
Hoarseness has a lifetime prevalence of 29.9 percent (percentage of people affected at some point in their life) and a point prevalence of 6.6 percent (percentage of people affected at a given point in time) in adults aged 65 years or under. Other cross-sectional studies have found a similar high lifetime prevalence of voice complaints of 28.8 percent in the general population. Higher prevalence rates of hoarseness have been shown in telemarketers (31%), aerobics instructors (44%), and teachers (58%). Women are more frequently affected than men, with a 60:40 F:M ratio.

Hoarseness may affect all age groups. Among children, prevalence rates vary from 3.9 percent to 23.4 percent with the most affected age range of 8 to 14 years. Voice problems persist four years or longer after identification in 38 percent of children with a voice disorder, suggesting an opportunity for early intervention. In addition, older adults are also at particular risk, with a point prevalence of 29 percent and a lifetime incidence up to 47 percent. Hoarseness may not be achieved and the clinician’s responsibilities will include minimizing hoarseness and optimizing patient function as well as assisting the patient in developing understanding and realistic expectations.

Lack of awareness about hoarseness and its causes are potential barriers to appropriate care. Among older adults, individuals commonly attribute their hoarseness to advancing age. Such assumptions may prevent or delay those with hoarseness from obtaining treatment. Improved education among all health professionals and efficient medical care are essential for reducing the health burden of hoarseness.

Inadequate insurance coverage has been cited as a cause of failure to seek treatment for both functional voice problems, as seen in singers, and life-threatening ones, as seen in cancer patients.

The primary outcomes considered in this guideline are improvement in vocal function and change in voice-related QOL. Secondary outcomes include complications and adverse events. Economic consequences, adherence to therapy, global QOL, return to work, improved communication function, and return health care visits were also considered. The high prevalence, significant individual and societal implications, diversity of interventions, and lack of consensus make this an important condition for an up-to-date, evidence-based practice guideline.

**Table 1 Interventions considered in hoarseness guideline development**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Targeted history</th>
<th>Physical examination</th>
<th>Laryngoscopy</th>
<th>Stroboscopy</th>
<th>Computed tomography (CT)</th>
<th>Magnetic resonance imaging (MRI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Watchful waiting/observation</td>
<td>Education/information</td>
<td>Voice therapy</td>
<td>Anti-reflux medications</td>
<td>Antibiotics</td>
<td>Steroids</td>
</tr>
<tr>
<td>Prevention</td>
<td>Botulinum toxin (BOTOX)</td>
<td>Voice training</td>
<td>Vocal hygiene</td>
<td>Education</td>
<td>Environmental measures</td>
<td></td>
</tr>
</tbody>
</table>

**BURDEN OF HOARSENESS**

Hoarseness has significant public health implications. Patients suffer social isolation, depression, and reduced disease-specific and general QOL. For example, patients with hoarseness caused by neurologic disorders (Parkinson disease, spasmodyc dysphonia, vocal tremor, or vocal fold paralysis) reported severe levels of voice handicap and reduced general health-related QOL, comparable to impairments observed in patients with congestive heart failure, angina, and chronic obstructive pulmonary disease.

Hoarseness may also impair work-related function. Approximately 28 million US workers have occupations that require use of voice. In the general population, 7.2 percent of individuals surveyed missed work for one or more days within the preceding year because of a problem with their voice. Among teachers this rate increases to 20 percent, resulting in a $2.5 billion loss among US adults because of missed work annually.

Medical, surgical, and behavioral treatment options exist for managing hoarseness. Among the general population, however, only 5.9 percent of those with hoarseness sought treatment. Similarly, only 14.3 percent of teachers had consulted a physician or speech-language pathologist for hoarseness, even though voice function is essential to their profession. In some circumstances, complete resolution of hoarseness may not be achieved and the clinician’s responsibilities will include minimizing hoarseness and optimizing patient function as well as assisting the patient in developing understanding and realistic expectations.

Lack of awareness about hoarseness and its causes are potential barriers to appropriate care. Among older adults, individuals commonly attribute their hoarseness to advancing age. Such assumptions may prevent or delay those with hoarseness from obtaining treatment. Improved education among all health professionals and efficient medical care are essential for reducing the health burden of hoarseness.

The primary outcomes considered in this guideline are improvement in vocal function and change in voice-related QOL. Secondary outcomes include complications and adverse events. Economic consequences, adherence to therapy, global QOL, return to work, improved communication function, and return health care visits were also considered. The high prevalence, significant individual and societal implications, diversity of interventions, and lack of consensus make this an important condition for an up-to-date, evidence-based practice guideline.

**GENERAL METHODS AND LITERATURE SEARCH**

The guideline was developed using an explicit and transparent a priori protocol for creating actionable statements based on supporting evidence and the associated balance of benefit and harm. The multidisciplinary guideline development panel was chosen to represent the fields of neurology, speech-language pathology, professional voice teaching, family medicine, pulmonology, geriatric medicine, nursing, internal medicine, otolaryngology–head and neck surgery, pediatrics, medicine, and consumers. Several group members had significant prior experience in developing clinical practice guidelines.

Several initial literature searches were performed through November 17, 2008 by AAO-HNSF staff using MEDLINE, The National Guidelines Clearinghouse (NGC) (www.guideline.gov), The Cochrane Library, Guidelines International Network (GIN), The Cumulative Index to Nursing and Allied Health Literature (CINAHL), and
Clinical practice guidelines were identified by a GIN, NGC, and MEDLINE search using “hoarseness[mh]” or “dysphonia[tw]” or “voice disorders[mh]” in any field showed 6032 potential articles:

1) Clinical practice guidelines were identified by a GIN, NGC, and MEDLINE search using “guideline” as a publication type or title word. The search identified eight guidelines with a topic of hoarseness or dysphonia. After eliminating articles that did not have hoarseness or dysphonia as the primary focus, no guidelines met quality criteria of being produced under the auspices of a medical association or organization and having an explicit method for ranking evidence and linking evidence to recommendations.

2) Systematic reviews were identified in MEDLINE using a validated filter strategy. That strategy initially yielded 92 potential articles. The final data set included 14 systematic reviews or meta-analyses (including two Cochrane systematic reviews) on hoarseness or dysphonia that were distributed to the panel members.

3) Randomized controlled trials were identified through the Cochrane Library (Cochrane Controlled Trials Register) and totaled 256 trials with “hoarseness” or “dysphonia” in any field.

4) Original research studies were identified by limiting the MEDLINE, CINAHL, and EMBASE search to articles on humans published in English. The resulting data set of 769 articles yielded 262 related to therapy, 256 to diagnosis, 205 to etiology, and 46 to prognosis. Results of all literature searches were distributed to guideline panel members at the first meeting, including electronic listings with abstracts (if available) of the searches for randomized trials, systematic reviews, and other studies. This material was supplemented, as needed, with targeted searches to address specific needs identified in other studies. This material was supplemented, as needed, with targeted searches to address specific needs identified in writing the guideline through February 8, 2009.

In a series of conference calls, the working group defined the scope and objectives of the proposed guideline. During the nine months devoted to guideline development ending in 2009, the group met twice, with interval electronic review and feedback on each guideline draft to ensure accuracy of content and consistency with standardized criteria for reporting clinical practice guidelines.

AAO-HNSF staff used GEM-COGS, the Guideline Implementability Appraisal and Extractor, to appraise adherence of the draft guideline to methodological standards, to improve clarity of recommendations, and to predict potential obstacles to implementation. Guideline panel members received summary appraisals in April 2009 and modified an advanced draft of the guideline.

The final draft practice guideline underwent extensive, multidisciplinary, external peer review. Comments were compiled and reviewed by the group chairpersons, and a modified version of the guideline was distributed and approved by the development panel. The recommendations contained in the practice guideline are based on the best available published data through February 2009. Where data were lacking, a combination of clinical experience and expert consensus was used. A scheduled review process will occur at five years from publication, or sooner if new compelling evidence warrants earlier consideration.

Classification of Evidence-Based Statements
Guidelines are intended to reduce inappropriate variations in clinical care, to produce optimal health outcomes for patients, and to minimize harm. The evidence-based approach to guideline development requires that the evidence supporting a policy be identified, appraised, and summarized and that an explicit link between evidence and statements be defined. Evidence-based statements reflect both the quality of evidence and the balance of benefit and harm that is anticipated when the statement is followed. The definitions for evidence-based statements are listed in Tables 2 and 3.

Guidelines are never intended to supersede professional judgment; rather, they may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. Less frequent variation in practice is expected for a “strong recommendation” than might be expected with a “recommendation.” “Options” offer the most opportunity for practice variability. Clinicians should always act in a way that they believe will best serve their patients’ interests and needs, regardless of guideline recommendations. They must also operate within their scope of practice and according to their training. Guidelines represent the best judgment of a team of experienced clinicians and methodologists addressing the scientific evidence for a particular topic.

Making recommendations about health practices involves value judgments on the desirability of various outcomes associated with management options. Values applied by the guideline panel sought to minimize harm and diminish unnecessary and inappropriate therapy. A major goal of the committee was to be transparent and explicit about how values were applied and to document the process.

Financial Disclosure and Conflicts of Interest
The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the AAO-HNS Foundation. Potential conflicts of interest for all panel members in the past five years were compiled and distributed before the first conference call. After review and discussion of these disclosures, the panel concluded that individuals with potential conflicts could remain on the panel if they: 1) reminded the panel of potential conflicts before any related discussion, 2) recused themselves from a related discussion if asked by the panel, and 3) agreed not to discuss any aspect of the guideline with industry before publication. Lastly, panelists were reminded that conflicts of interest extend beyond financial relationships and may include personal experiences, how a participant earns a living, and the participant’s previously established “stake” in an issue.
HOARSENESS (DYSPHONIA) GUIDELINE
ACTION STATEMENTS

Each action statement is organized in a similar fashion: statement in boldface type, followed by an italicized statement on the strength of the recommendation. Several paragraphs then discuss the evidence base supporting the statement, concluding with an “evidence profile” of aggregate evidence quality, benefit-harm assessment, and statement of costs. Lastly, there is an explicit statement of the value judgments, the role of patient preferences, and a repeat statement of the strength of the recommendation. An overview of evidence-based statements in the guideline and their interrelationship is shown in Table 4.

The role of patient preference in making decisions deserves further clarification. For some statements the evidence base demonstrates clear benefit, which would minimize the role of patient preference. If the evidence is weak or benefits are unclear, however, not all informed patients might opt to follow the suggestion. In these cases, the practice of shared decision making, where the management decision is made by a collaborative effort between the clinician and the informed patient, becomes more useful. Factors related to patient preference include (but are not limited to) absolute benefits (number needed to treat), adverse effects (number needed to harm), cost of drugs or tests, frequency and duration of treatment, and desire to take or avoid antibiotics. Comorbidity can also impact patient preferences by several mechanisms, including the potential for drug-drug interactions when planning therapy.

STATEMENT 1. DIAGNOSIS: Clinicians should diagnose hoarseness (dysphonia) in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related QOL. Recommendation based on observational studies with a preponderance of benefit over harm.

Supporting Text

The purpose of this statement is to promote awareness of hoarseness (dysphonia) by all clinicians as a condition that may require intervention or additional investigation. The proposed diagnosis (dysphonia) is based on strictly clinical criteria, and does not require testing or additional investigations. Hoarseness is a symptom reported by the patient or proxy, identified by the clinician, or both.

Table 2
Guideline definitions for evidence-based statements

<table>
<thead>
<tr>
<th>Statement</th>
<th>Definition</th>
<th>Implication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong rec.</td>
<td>A strong recommendation means the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits, in the case of a strong negative recommendation) and that the quality of the supporting evidence is excellent (Grade A or B*). In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.</td>
<td>Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.</td>
</tr>
<tr>
<td>Rec.</td>
<td>A recommendation means the benefits exceed the harms (or that the harms exceed the benefits, in the case of a negative recommendation), but the quality of evidence is not as strong (Grade B or C*). In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.</td>
<td>Clinicians should also generally follow a recommendation, but should remain alert to new information and sensitive to patient preferences.</td>
</tr>
<tr>
<td>Option</td>
<td>An option means either that the quality of evidence that exists is suspect (Grade D*) or that well-done studies (Grade A, B, or C*) show little clear advantage to one approach vs another.</td>
<td>Clinicians should be flexible in their decision making regarding appropriate practice, although they may set bounds on alternatives; patient preference should have a substantial influencing role.</td>
</tr>
</tbody>
</table>

*See Table 3 for definition of evidence grades.
Some patients with objectively minor changes may be unable to work and have a significant decrement in QOL. Others with significant disease such as malignancy may have minimal functional impairment of their voice. Of patients with laryngeal cancer, 52 percent thought their hoarseness was harmless and delayed seeing a physician.36 Accordingly, patients with minimal objective voice change and significant complaints as well as patients with limited complaints but with objective alterations of voice quality warrant evaluation.

Patients with hoarseness may experience discomfort with speaking, increased phonatory effort, and weak voice, as well as altered quality such as wobbly or shaky voice, breathiness, and raspiness.20,37,38 While a breathy voice may signify vocal fold paralysis or another cause of incomplete vocal fold closure, a strained voice with altered pitch or pitch breaks is common in spasmodic dysphonia.39 Changes in voice quality may be limited to the singing voice and not affect the speaking voice. Among infants and young children, an abnormal cry may signify underlying pathology including vocal fold paralysis, laryngeal papilloma, or other systemic conditions.

Listening to the voice (perceptual evaluation) in a critical and objective manner may provide important diagnostic information. Characterizing the patient’s complaint and voice quality is important for assessing hoarseness severity and for differentiating among specific causes of hoarseness, such as muscle tension dysphonia and spasmodic dysphonia.40,41

Hoarseness may impair communication. Difficulty being heard and understood while using the telephone has been reported in the geriatric population.20,38 Trouble being heard in groups and problems being understood are also common complaints among hoarse patients.37 Consequently, patients describe less confidence, decreased socialization, and impaired work-related function.1,37

Hoarseness may lead to decreased voice-related QOL and a decrement in physical, social, and emotional aspects.

### Table 3
Evidence quality for grades of evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Evidence quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Well-designed randomized controlled trials or diagnostic studies performed on a population similar to the guideline’s target population</td>
</tr>
<tr>
<td>B</td>
<td>Randomized controlled trials or diagnostic studies with minor limitations; overwhelmingly consistent evidence from observational studies</td>
</tr>
<tr>
<td>C</td>
<td>Observational studies (case-control and cohort design)</td>
</tr>
<tr>
<td>D</td>
<td>Expert opinion, case reports, reasoning from first principles (bench research or animal studies)</td>
</tr>
<tr>
<td>X</td>
<td>Exceptional situations where validating studies cannot be performed and there is a clear preponderance of benefit over harm</td>
</tr>
</tbody>
</table>

### Table 4
Outline of guideline action statements

<table>
<thead>
<tr>
<th>Hoarseness (dysphonia) (statement number)</th>
<th>Statement strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Diagnosis</td>
<td></td>
</tr>
<tr>
<td>a. Diagnosis (Statement 1)</td>
<td>Recommendation</td>
</tr>
<tr>
<td>b. Modifying factors (Statement 2)</td>
<td>Recommendation</td>
</tr>
<tr>
<td>c. Laryngoscopy and hoarseness (Statement 3A)</td>
<td>Option</td>
</tr>
<tr>
<td>d. Indications for laryngoscopy (Statement 3B)</td>
<td>Recommendation against</td>
</tr>
<tr>
<td>e. Imaging prior to laryngoscopy (Statement 4)</td>
<td>Recommendation against</td>
</tr>
<tr>
<td>II. Medical therapy</td>
<td></td>
</tr>
<tr>
<td>a. Anti-reflux therapy for hoarseness in the absence of GERD or chronic laryngitis (Statement 5A)</td>
<td>Recommendation against</td>
</tr>
<tr>
<td>b. Anti-reflux therapy with chronic laryngitis (Statement 5B)</td>
<td>Option</td>
</tr>
<tr>
<td>c. Corticosteroid therapy (Statement 6)</td>
<td>Recommendation against</td>
</tr>
<tr>
<td>d. Antimicrobial therapy (Statement 7)</td>
<td>Strong recommendation against</td>
</tr>
<tr>
<td>III. Voice therapy</td>
<td></td>
</tr>
<tr>
<td>a. Laryngoscopy prior to beginning (Statement 8A)</td>
<td>Recommendation</td>
</tr>
<tr>
<td>b. Advocating for (Statement 8B)</td>
<td>Strong recommendation</td>
</tr>
<tr>
<td>IV. Invasive therapies</td>
<td></td>
</tr>
<tr>
<td>a. Advocating surgery in selected patients (Statement 9)</td>
<td>Recommendation</td>
</tr>
<tr>
<td>b. Botulinum toxin for adductor spasmodic dysphonia (Statement 10)</td>
<td>Recommendation</td>
</tr>
<tr>
<td>V. Prevention (Statement 11)</td>
<td>Option</td>
</tr>
</tbody>
</table>
of global QOL similar to those associated with other chronic diseases, such as congestive heart failure and chronic obstructive pulmonary disease.7,8

Clinicians should consider input from proxies when diagnosing hoarseness (dysphonia). Of patients with vocal fold cancer, 40 percent waited three months before seeking medical attention for their hoarseness. Furthermore, 16.7 percent only sought treatment after encouragement from other people.36 These data highlight the fact that hoarseness may not be recognized by the patient.

Children and patients with cognitive impairment or severe emotional burden may be unaware or unable to recognize and report on their own hoarseness.42 QOL studies in older adults have required proxy input in approximately 25 percent of the geriatric population.43 While self-report measures for hoarseness are available, patients may be unable to complete them.44-46 In these cases, proxy judgments by significant others about QOL are a good alternative.42 Moderate agreement has been shown between adult patients and their communication partners on the Voice Handicap Index. Parent proxy self-report measures have also been validated for use in the pediatric population.38,47

When evaluating a patient with hoarseness, the clinician should obtain a detailed medical history (Table 5) and review current medications (Table 6) as this information may identify the cause of the hoarseness (dysphonia) or an alternative underlying condition that may warrant attention.

Evidence profile for Statement 1: Diagnosis

- Aggregate evidence quality: Grade C, observational studies for symptoms with one systematic review of QOL in

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Pertinent medical history for assessing a patient with hoarseness48-50</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Voice-specific questions</strong></td>
<td>Did your problem start suddenly or gradually?</td>
</tr>
<tr>
<td></td>
<td>Is your voice ever normal?</td>
</tr>
<tr>
<td></td>
<td>Do you have pain when talking?</td>
</tr>
<tr>
<td></td>
<td>Does your voice deteriorate or fatigue with use?</td>
</tr>
<tr>
<td></td>
<td>Does it take more effort to use your voice?</td>
</tr>
<tr>
<td></td>
<td>What is different about the sound of your voice?</td>
</tr>
<tr>
<td></td>
<td>Do you have a difficult time getting loud or projecting?</td>
</tr>
<tr>
<td></td>
<td>Have you noticed changes in your pitch or range?</td>
</tr>
<tr>
<td></td>
<td>Do you run out of air when talking?</td>
</tr>
<tr>
<td></td>
<td>Does your voice crack or break?</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Globus pharyngeus (persisting sensation of lump in throat)</td>
</tr>
<tr>
<td></td>
<td>Dysphagia</td>
</tr>
<tr>
<td></td>
<td>Sore throat</td>
</tr>
<tr>
<td></td>
<td>Chronic throat clearing</td>
</tr>
<tr>
<td></td>
<td>Cough</td>
</tr>
<tr>
<td></td>
<td>Odynophagia (pain with swallowing)</td>
</tr>
<tr>
<td></td>
<td>Nasal drainage</td>
</tr>
<tr>
<td></td>
<td>Post-nasal drainage</td>
</tr>
<tr>
<td></td>
<td>Non-anginal chest pain</td>
</tr>
<tr>
<td></td>
<td>Acid reflux</td>
</tr>
<tr>
<td></td>
<td>Regurgitation</td>
</tr>
<tr>
<td></td>
<td>Heartburn</td>
</tr>
<tr>
<td></td>
<td>Waterbrash (sudden appearance of salty liquid in the mouth)</td>
</tr>
<tr>
<td></td>
<td>Halitosis (&quot;bad breath&quot;)</td>
</tr>
<tr>
<td></td>
<td>Fever</td>
</tr>
<tr>
<td></td>
<td>Hemoptysis</td>
</tr>
<tr>
<td></td>
<td>Weight loss</td>
</tr>
<tr>
<td></td>
<td>Night sweats</td>
</tr>
<tr>
<td></td>
<td>Otalgia (ear pain)</td>
</tr>
<tr>
<td></td>
<td>Difficulty breathing</td>
</tr>
<tr>
<td><strong>Medical history relevant to hoarseness</strong></td>
<td>Occupation and/or avocation requiring extensive voice use (ie, teacher, singer)</td>
</tr>
<tr>
<td></td>
<td>Absenteeism from occupation due to hoarseness</td>
</tr>
<tr>
<td></td>
<td>Prior episode(s) of hoarseness</td>
</tr>
<tr>
<td></td>
<td>Relationship of instrumentation (intubation, etc) to onset of hoarseness</td>
</tr>
<tr>
<td></td>
<td>Relationship of prior surgery to neck or chest to onset of hoarseness</td>
</tr>
<tr>
<td></td>
<td>Cognitive impairment (requirement for proxy historian)</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
</tr>
<tr>
<td><strong>Acute conditions</strong></td>
<td>Infection of the throat and/or larynx: viral, bacterial, fungal</td>
</tr>
<tr>
<td></td>
<td>Foreign body in larynx, trachea, or esophagus</td>
</tr>
<tr>
<td></td>
<td>Neck or laryngeal trauma</td>
</tr>
<tr>
<td><strong>Chronic conditions</strong></td>
<td>Stroke</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
</tr>
<tr>
<td></td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td></td>
<td>Diseases from the Parkinson’s Plus family (progressive supranuclear palsy, etc)</td>
</tr>
<tr>
<td></td>
<td>Myasthenia gravis</td>
</tr>
<tr>
<td></td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td></td>
<td>Amyotrophic lateral sclerosis (ALS)</td>
</tr>
<tr>
<td></td>
<td>Testosterone deficiency</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 5</th>
<th>continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allergic rhinitis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chronic rhinitis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Hypertension</strong> (because of certain medications used for this condition)</td>
<td></td>
</tr>
<tr>
<td><strong>Schizophrenia</strong> (because of anti-psychotics used for mental health problems)</td>
<td></td>
</tr>
<tr>
<td><strong>Osteoporosis</strong> (because of certain medications used for this condition)</td>
<td></td>
</tr>
<tr>
<td><strong>Asthma, chronic obstructive pulmonary disease</strong> (because of use of inhaled steroids)</td>
<td></td>
</tr>
<tr>
<td><strong>Aneurysm of thoracic aorta</strong> (rare cause)</td>
<td></td>
</tr>
<tr>
<td><strong>Laryngeal cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Lung cancer</strong> (or metastasis to the lung)</td>
<td></td>
</tr>
<tr>
<td><strong>Thyroid cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Hypothyroidism and other endocrinopathies</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Vocal fold nodules</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Vocal fold paralysis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Vocal abuse</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chemical laryngitis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chronic tobacco use</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sjögren syndrome</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **Alcohol** (moderate to heavy use or abuse)**
Recommendation based on observational studies

STATEMENT 2. MODIFYING FACTORS: Clinicians should assess the patient with hoarseness by history and/or physical examination for factors that modify management such as one or more of the following: recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, a history of tobacco abuse, and occupation as a singer or vocal performer. Recommendation based on observational studies with a preponderance of benefit over harm.

Supporting Text

The term “modifying factors” as used in this recommendation refers to details elicited by history taking or physical examination that provide a clue to the presence of an important underlying etiology of hoarseness (dysphonia) that may lead to a change in management. The history and physical examination of the patient with hoarseness may provide insight into the nature of the patient’s condition prior to the initiation of a more in-depth evaluation.

Surgery on the cervical spine via an anterior approach has been associated with a high incidence of voice problems. Recurrent laryngeal nerve paralysis has been reported to range from 1.27 percent to 2.7 percent.63-65 Assessment with laryngoscopy suggests an even higher incidence.56 The incidence of hoarseness immediately following anterior cervical spine surgery may be as high as 50 percent.67 Hoarseness resulting from anterior cervical spine surgery may or may not resolve over time.68,69

Thyroid surgery has been associated with voice disorders. Patients with thyroid disease requiring surgery may have hoarseness and identifiable abnormalities on indirect laryngoscopy prior to surgery.70 Thyroidectomy may cause hoarseness as a result of recurrent laryngeal nerve paralysis in up to 2.1 percent of patients.71 Surgery in the anterior neck can also lead to injury to the superior laryngeal nerve with resulting voice alteration, although this is uncommon.72

Carotid endarterectomy is frequently associated with postoperative voice problems,73 and may result in recurrent laryngeal nerve damage in up to 6 percent of patients.74,75 Surgery to achieve an urgent airway or on the larynx directly may alter its structure, resulting in abnormal voice.76,77

Surgical procedures not involving the neck may also result in hoarseness (dysphonia). Hoarseness following cardiac surgery is a common problem, occurring in 17 percent to 31 percent of patients.78,79 Hoarseness may result from changes in position or manipulation of the endotracheal tube or from lengthy procedures.78 Recurrent laryngeal nerve injury occurs in about 1.4 percent of patients during cardiac surgery.78 The left recurrent laryngeal nerve is damaged more commonly than the right as it extends into the chest and loops under the arch of the aorta. Damage may result from direct physical injury to the nerve or hypothermic injury due to cold cardioplegia.80

Surgery for esophageal cancer frequently results in damage to the recurrent laryngeal nerve with subsequent hoarseness. In one study, 51 of 141 patients undergoing esophagectomy for cancer had laryngeal nerve paralysis, with 30 of these patients having persistent paralysis one year following surgery.81 The implantation of vagal nerve stimulators for intractable seizures has been associated with hoarseness in as many as 28 percent of patients.82

Prolonged endotracheal intubation has been associated with hoarseness. Direct laryngoscopy of patients intubated for more than four days (mean nine days) demonstrates that 94 percent of patients have laryngeal nerve injury.83 The injury patterns seen in the patients with prolonged intubation include laryngeal edema and posterior and medial vocal fold ulceration. As many as 44 percent of patients with prolonged intubation may develop vocal fold granulomas within four weeks of being extubated. In this study, 18

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of impact on voice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumadin, thrombolytics, phosphodiesterase-5 inhibitors</td>
<td>Vocal fold hematoma51-53</td>
</tr>
<tr>
<td>Biphosphonates</td>
<td>Chemical laryngitis64</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme inhibitors</td>
<td>Cough65</td>
</tr>
<tr>
<td>Antihistamines, diuretics, anticholinergics</td>
<td>Drying effect on mucosa56,57</td>
</tr>
<tr>
<td>Danocrine, testosterone</td>
<td>Sex hormone production/ utilization alteration58,59</td>
</tr>
<tr>
<td>Antipsychotics, atypical antipsychotics</td>
<td>Laryngeal dystonia60,61</td>
</tr>
<tr>
<td>Inhaled steroids</td>
<td>Dose-dependent mucosal irritation,62 fungal laryngitis</td>
</tr>
</tbody>
</table>

voice disorders and two systematic reviews on medication side effects

- Benefit: Identify patients who may benefit from treatment or from further investigation to identify underlying conditions that may be serious, promote prompt recognition and treatment, and discourage the perception of hoarseness as a trivial condition that does not warrant attention
- Harm: Potential anxiety related to diagnosis
- Cost: Time expended in diagnosis, documentation, and discussion
- Benefits-harm assessment: Preponderance of benefits over harm
- Value judgments: None
- Role of patient preference: Limited
- Intentional vagueness: None
- Exclusions: None
- Policy Level: Recommendation

Table 6: Medications that may cause hoarseness

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of impact on voice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumadin, thrombolytics, phosphodiesterase-5 inhibitors</td>
<td>Vocal fold hematoma51-53</td>
</tr>
<tr>
<td>Biphosphonates</td>
<td>Chemical laryngitis64</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme inhibitors</td>
<td>Cough65</td>
</tr>
<tr>
<td>Antihistamines, diuretics, anticholinergics</td>
<td>Drying effect on mucosa56,57</td>
</tr>
<tr>
<td>Danocrine, testosterone</td>
<td>Sex hormone production/ utilization alteration58,59</td>
</tr>
<tr>
<td>Antipsychotics, atypical antipsychotics</td>
<td>Laryngeal dystonia60,61</td>
</tr>
<tr>
<td>Inhaled steroids</td>
<td>Dose-dependent mucosal irritation,62 fungal laryngitis</td>
</tr>
</tbody>
</table>
percent of patients had prolonged true vocal fold immobility for at least four weeks after extubation.\textsuperscript{84} Another study following a large group of patients for several years found chronic phonatory dysfunction in many patients after long-term intubation.\textsuperscript{85}

Short-term intubation for general anesthesia may result in hoarseness and vocal fold pathology in over 50 percent of cases.\textsuperscript{86} While most symptoms resolved after five days, prolonged symptoms may result from vocal fold granuloma. If hoarseness persists, the remoteness of the index event may confound the evaluating clinician. Use of a laryngeal mask airway may reduce postsurgical complaints of discomfort, but does not objectively reduce hoarseness.\textsuperscript{87}

Long-term intubation of neonates may result in voice problems related to arytenoid and posterior commissure ulceration and cartilage erosion.\textsuperscript{88} Children with a history of prolonged intubation may have long-term complications of hoarseness and arytenoid dysfunction.

Voice disorders are common in older adults and significantly affect the QOL in these patients.\textsuperscript{21} Vocal fold atrophy with resulting hoarseness (dysphonia) is a common disorder of older adults and is frequently undiagnosed by primary care providers.\textsuperscript{89,90} Hoarseness resulting from neurologic disorders such as cerebral vascular accident and Parkinson disease is also more common in elderly patients.\textsuperscript{91,94} Multiple sclerosis can lead to hoarseness in patients of any age.\textsuperscript{95}

Chronic hoarseness (dysphonia) is quite common in young children and has an adverse impact on QOL.\textsuperscript{96} Prevalence ranges from 15 percent to 24 percent of the population.\textsuperscript{17,97} In one study, 77 percent of hoarse children had vocal fold nodules.\textsuperscript{17} These may persist into adolescence if not properly treated.\textsuperscript{96} Craniofacial anomalies such as orofacial clefts are associated with abnormal voice,\textsuperscript{99} but these are frequently resonance disorders requiring very different therapies than for hoarse children with normal anatomical development.

Hoarseness or dysphonia in infants may be recognized only by an abnormal cry, and suspicion of such symptoms should prompt consultation with an otolaryngologist.\textsuperscript{100} When infants do present with hoarseness, underlying etiologies such as birth trauma, an intracranial process such as Arnold-Chiari malformation or posterior fossa mass, or mediastinal pathology should be considered.\textsuperscript{101}

Hoarseness in tobacco smokers is associated with an increased frequency of polypoid vocal fold lesions and head and neck cancer.\textsuperscript{102} Accordingly, this requires an expedient assessment for malignancy as the potential cause of hoarseness. In addition, in patients treated with external beam radiation for glottic cancer, radiation treatment is associated with hoarseness in about 8 percent of cases.\textsuperscript{103,104}

Patients who use inhaled corticosteroids for the treatment of asthma or chronic obstructive pulmonary disease may present to a clinician with hoarseness that is a side effect of therapy either from direct irritation or from a fungal infection of the larynx.\textsuperscript{105}

Singers or vocal performers should be identified by the clinician when eliciting a history from the hoarse patient. These patients have significant impairment with symptoms that may be subclinical in other patients. They may be more subject to voice over-use or have a different etiology for their symptoms, and hoarseness may have a more significant impact on their QOL or ability to earn income. For example, while hoarseness is relatively rare following thyroid surgery, there are objective, measurable changes in the voice of most patients that could affect pitch and the ability to sing.\textsuperscript{106} Singers are also prone to develop microvascular ectasias that affect voice and require specific therapy.\textsuperscript{107}

To a slightly lesser degree, individuals in a number of other occupations or avocations, such as teachers and clergy, depend on voice use. As an example, over 50 percent of teachers have hoarseness, and vocal overuse is a common, but not exclusive, etiologic factor.\textsuperscript{108} Clinicians should inquire about an individual’s voice use in order to determine the degree to which altered voice quality may impact the individual professionally.

**Evidence profile for Statement 2: Modifying Factors**
- Aggregate evidence quality: Grade C, observational studies
- Benefit: To identify factors early in the course of management that could influence the timing of diagnostic procedures, choice of interventions, or provision of follow-up care
- Harm: None
- Cost: None
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Importance of history taking and identifying modifying factors as an essential component of providing quality care
- Role of patient preferences: Limited or none
- Intentional vagueness: None
- Exclusions: None
- Policy level: Recommendation

**STATEMENT 3A. LARYNGOSCOPY AND HOARSENESS:** Clinicians may perform laryngoscopy, or may refer the patient to a clinician who can visualize the larynx, at any time in a patient with hoarseness. \textit{Option based on observational studies, expert opinion, and a balance of benefit and harm.}

**STATEMENT 3B. INDICATIONS FOR LARYNGOSCOPY:** Clinicians should visualize the patient’s larynx, or refer the patient to a clinician who can visualize the larynx, when hoarseness fails to resolve by a maximum of three months after onset, or irrespective of duration if a serious underlying cause is suspected. \textit{Recommendation based on observational studies, expert opinion, and a preponderance of benefit over harm.}
diagnosis and the benefit of early detection have led the British medical system to employ fast-track screening clinics for laryngeal cancer that mandate laryngoscopy within 14 days of suspicion of laryngeal cancer.\textsuperscript{111,112} Fungal laryngitis from inhalers and other causes is best diagnosed with laryngoscopy and must be distinguished from malignancy.\textsuperscript{113}

Unilateral vocal fold paralysis causes breathy hoarseness and is often caused by thoracic, cervical, or brain tumors that either compress or invade the vagus nerve or its branches that innervate the larynx. Stroke may also present with hoarseness due to vocal fold paralysis. Vocal fold paralysis is routinely identified, characterized, and followed by laryngoscopy.\textsuperscript{79,114}

In patients with cranial nerve deficits or neuromuscular changes, laryngoscopy is useful to identify neurologic causes of vocal dysfunction.\textsuperscript{115} Benign vocal fold lesions such as vocal fold cysts, nodules, and polyps are readily detected on laryngoscopy. Visualization of the larynx may also provide supporting evidence in the diagnosis of laryngopharyngeal reflex.\textsuperscript{116}

Hoarseness caused by neurologic or motor neuron disease such as Parkinson disease, amyotrophic lateral sclerosis, and spasmodic dysphonia may have laryngoscopic findings that the clinician can identify to initiate management of the underlying disease.\textsuperscript{117} Office laryngoscopy is also a critical tool in the evaluation of the aging voice.

Neonates with hoarseness should undergo laryngoscopy to identify vocal fold paralysis,\textsuperscript{118} laryngeal webs,\textsuperscript{119} or other congenital anomalies that might affect their ability to swallow or breathe.\textsuperscript{120}

Hoarseness in children is rarely a sign of a serious underlying condition and is more likely the result of a benign lesion of the larynx such as a vocal fold polyp, nodules, or cyst.\textsuperscript{121} However, determining if laryngeal papilloma is the etiology of hoarseness in a child is particularly important given the high potential for life-threatening airway obstruction and the potential for malignant transformation.\textsuperscript{122} A hoarse child with other symptoms such as stridor, airway obstruction, or dysphagia may have a serious underlying problem such as a Chiari malformation,\textsuperscript{123} hydrocephalus, skull base tumors, or a compressing neck or mediastinal mass. Persistent hoarseness in children may be a symptom of vocal fold paralysis with underlying etiologies that include neck masses, congenital heart disease, or previous cardiothoracic, esophageal, or neck surgery.\textsuperscript{124}
cern is by visualization of the vocal folds with laryngoscopy.

The major cause of community-acquired hoarseness is viral. Symptoms from viral laryngitis typically last 1 to 3 weeks.\textsuperscript{125,126} Symptoms of hoarseness persisting beyond this time warrant further evaluation to insure that no malignancy or morbid conditions are missed and to allow further treatment to be initiated based on specific benign pathologies if indicated. One population-based cohort study\textsuperscript{127} and one large case-control study\textsuperscript{128} have shown that delays in diagnosis of laryngeal cancer lead to higher stages of disease at diagnosis and worse prognosis. In the cohort study, delay longer than three months led to poorer survival.

The expediency of laryngoscopy also depends on patient considerations. Singers, performers, and patients whose livelihood depends upon their voice will not be able to wait several weeks for their hoarseness to resolve as they may be unable to work in the interim. In fact, a number of professionals with high vocal demands may benefit from immediate evaluation.

Even in the absence of serious concern or patient considerations indicating immediate laryngoscopy, persistent hoarseness should be evaluated to rule out significant pathology such as cancer or vocal fold paralysis. In the absence of immediate concern, there is little guidance from the literature on the proper length of time a hoarse patient can or should be observed before visualization of the larynx is mandated. The working group weighed the risk of delayed diagnosis against the potential over-utilization of resources and selected a fairly long window of three months prior to mandating laryngoscopy. This safety net approach, based on expert opinion, was designed to address the main concern of the working group that many patients with persistent hoarseness are currently experiencing delayed diagnosis or are not undergoing laryngoscopy at all.

**Techniques for Visualizing the Larynx**

Different techniques are available for laryngoscopy and confer varying levels of risk. The working group does not have recommendations as to the preferred method. Choice of method is at the discretion of the evaluating clinician.

Office laryngoscopy can be performed transorally with a mirror or rigid endoscope, transnasally with a flexible fiberoptic or distal-chip laryngoscope, and with either halomirror or rigid endoscope, transnasally with a flexible fiberoptic or stroboscopic light application.\textsuperscript{129} The surface and mobility of the vocal folds are well assessed with these tools.

Stroboscopy is used to visualize the vocal folds as they vibrate, allowing for an assessment of both anatomy and function during the act of phonation.\textsuperscript{130} When hoarseness symptoms are out of proportion to the laryngoscopic examination, stroboscopy should be considered. The addition of stroboscopic light allows for an assessment of the pliability of the vocal folds, making additional pathologies such as vocal fold scar easy to identify. Stroboscopy has resulted in altered diagnosis in 47 percent of cases,\textsuperscript{131} and stroboscopic parameters aid in the differentiation of specific vocal fold pathology, such as polyps and cysts.\textsuperscript{132} Surgical endoscopy with magnification (microlaryngoscopy) is utilized more often when more detailed examination, manipulation, or biopsy of the structures is required.\textsuperscript{133}

In the adult, visualization by indirect mirror examination may be limited by patient tolerance and photo documentation is not possible. Discomfort in transnasal laryngoscopy is usually mitigated by the application of topical decongestant and/or anesthetic such as lidocaine. A study of 1208 patients evaluated by fiberoptic laryngoscopy for assessment of vocal fold paralysis after thyroidectomy showed no significant adverse events.\textsuperscript{134} No other reports of significant risks of fiberoptic laryngoscopy were found in a detailed MEDLINE search using key words: laryngoscopy, complications, risk, and adverse events. Transoral examinations of the larynx may be preceded by topical lidocaine to the throat and carries similarly minimal risk.

Operative laryngoscopy carries more substantial risk but generally allows for ease of tissue manipulation and biopsy. Risks associated with direct laryngoscopy with general anesthesia, include airway distress; dental trauma; oral cavity, oropharyngeal, and hypopharyngeal trauma; tongue dysesthesia; taste changes; and cardiovascular risk.\textsuperscript{135-137} The cost of direct laryngoscopy is substantially greater than that of office-based laryngoscopy due to the additional costs of staff, equipment, and additional care required.\textsuperscript{138-140}

Special consideration is given to children for whom laryngoscopy requires either advanced skill or a specialized setting. With the advent of small-diameter flexible laryngoscopes, awake, flexible laryngoscopy can be employed in the clinic in children as young as newborns but is subject to the skill of the clinician and comfort with children. The advantage is that this examination allows for evaluation of both anatomy and function of the larynx in the hoarse child. Direct laryngoscopy under anesthesia with or without a microscope may be used to verify flexible fiberoptic findings, manage laryngeal papillomas or other vocal fold lesions, and further define laryngeal pathology such as congenital anomalies of the larynx. Intraoperative palpation of the cricoarytenoid joint may also help differentiate between vocal fold paralysis and fixation.

**Evidence profile for Statement 3A: Laryngoscopy and Hoarseness**

- **Aggregate evidence quality:** Grade C, based on observational studies
- **Benefit:** Visualization of the larynx to improve diagnostic accuracy and allow comprehensive evaluation
- **Harm:** Risk of laryngoscopy, patient discomfort
- **Cost:** Procedural expense
- **Benefits-harm assessment:** Balance of benefit and harm
- **Value judgments:** Laryngoscopy is an important tool for evaluating voice complaints and may be performed at any time in the patient with hoarseness
- **Intentional vagueness:** None
Role of patient preferences: Substantial; the level of patient concern should be considered in deciding when to perform laryngoscopy
Exclusions: None
Policy level: Recommendation

Evidence profile for Statement 3B: Indications for Laryngoscopy

- Aggregate evidence quality: Grade C, observational studies on the natural history of benign laryngeal disorders; grade C for observational studies plus expert opinion on defining what constitutes a serious underlying condition
- Benefit: Avoid missed or delayed diagnosis of serious conditions in patients without additional signs or symptoms to suggest underlying disease; permit prompt assessment of the larynx when serious concern exists
- Harm: Potential for up to a three-month delay in diagnosis; procedure-related morbidity
- Cost: Procedural expense
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: A need to balance timely diagnostic intervention with the potential for over-utilization and excessive cost. The guideline panel debated on the maximum duration of hoarseness prior to mandated evaluation and opted to select a “safety net approach” with a generous time allowance (three months), but options to proceed promptly based on clinical circumstances
- Intentional vagueness: The term “serious underlying concern” is subject to the discretion of the clinician. Some conditions are clearly serious, but in other patients, the seriousness of the condition is dependent on the patient. Intentional vagueness was incorporated to allow for clinical judgment in the expediency of evaluation
- Role of patient preferences: Limited
- Exclusions: None
- Policy level: Recommendation

STATEMENT 4. IMAGING: Clinicians should not obtain computed tomography (CT) or magnetic resonance imaging (MRI) of the patient with a primary complaint of hoarseness prior to visualizing the larynx. Recommendation against imaging based on observational studies of harm, absence of evidence concerning benefit, and a preponderance of harm over benefit.

Supporting Text

The purpose of this statement is not to discourage the use of imaging in the comprehensive work-up of hoarseness, but rather to emphasize that it should be used to assess for specific pathology after the larynx has been visualized.

Laryngoscopy is the primary diagnostic modality for evaluating patients with hoarseness. Imaging studies, including CT and MRI, have also been used, but are unnecessary in most patients because most hoarseness is self-limited or caused by pathology that can be identified by laryngoscopy. The value of imaging procedures before laryngoscopy is undocumented; no articles were found in the systematic literature review for this guideline regarding the diagnostic yield of imaging studies prior to laryngeal examination. Conversely, the risk of imaging studies is well documented.

The risk of radiation-induced malignancy from CT scans is small but real. More than 62 million CT scans per year are obtained in the United States for all indications, including 4 million performed on children (nationwide evaluation of x-ray trends). In a study of 400,000 radiation workers in the nuclear industry who were exposed to an average dose of 20 mSv (a typical organ dose from a single CT scan for an adult), a significant association was reported between the radiation dose and mortality from cancer in this cohort. These risks were quantitatively similar to those reported for atomic bomb survivors. Children have higher rates of malignancy and a longer lifespan in which radiation-induced malignancies can develop. It is estimated that about 0.4 percent of all cancers in the United States may be attributable to the radiation from CT scans. The risk may be higher (1.5% to 2%) if we adjust this estimate based on our current use of CT scans.

There are also risks associated with IV contrast dye used to increase diagnostic yield of CT scans. Allergies to contrast dye are common (5% to 8% of the population). Severe, life-threatening reactions, including anaphylaxis, occur in 0.1 percent of people receiving iodinated contrast material, with a death rate of up to one in 29,500 people.

While MRI has no radiation effects, it is not without risk. A review of the safety risks of MRI details five main classes of injury: 1) projectile effects (anything metal that gets attracted by the magnetic field); 2) twisting of indwelling metallic objects (cerebral artery clips, cochlear implants, or shrapnel); 3) burning (electrical conductive material in contact with the skin with an applied magnetic field, ie, EKG electrodes or medication patches); 4) artifacts (radiofrequency effects from the device itself simulating pathology); and 5) device malfunction (pacemakers will fire inappropriately or work at an elevated frequency, thus distorting cardiac conduction).

The small confines of the MRI scanner may lead to claustrophobia and anxiety. Some patients, children in particular, require sedation (with its associated risks). The gadolinium contrast used for MRI rarely induces anaphylactic reactions, but there is recent evidence of renal toxicity with gadolinium in patients with pre-existing renal disease. Transient hearing loss has been reported, but this is usually avoided with hearing protection. The costs of MRI, however, are significantly more than CT scanning. Despite these risks and their considerable cost, cross-sectional imaging studies are being used with increasing frequency.

After laryngoscopy, evidence does support the use of imaging to further evaluate 1) vocal fold paralysis or 2) a
mass or lesion of the vocal fold or larynx that suggests malignancy or airway obstruction.\(^{159}\) If vocal fold palsy is noted and recent surgery can explain the cause of the palsy, imaging studies are generally not useful. If the health care provider suspects a lesion along the recurrent laryngeal nerve, imaging studies are indicated.

Unexplained vocal fold paralysis found on laryngoscopy warrants imaging the skull base to the thoracic inlet/arch of the aorta. Including these anatomic areas allows for evaluation of the entire path of the recurrent laryngeal nerve as it loops around the arch of the aorta on the left side. On the right, it will show any lesions in the lung apex along the course of the right recurrent laryngeal nerve as it loops around the subclavian artery. One study showed that a complete radiographic work-up improved rates of diagnosis,\(^{160}\) but there is no consensus on whether CT or MRI is better for evaluating the recurrent laryngeal nerve.\(^{161,162}\)

Lesions at the skull base and brain are best evaluated using an MRI of the brain and brain stem with gadolinium enhancement. If a patient presents with additional lower cranial nerve palsy, the skull base, particularly the jugular foramen (CN IX, X, XI), should be evaluated.\(^{159}\)

Primary lesions of the larynx, pharynx, subglottis, thyroid, and any pertinent lymph node groups can also be evaluated by imaging the entire area. Intravenous contrast may help to distinguish vascular lesions from normal pathology on CT. Due to the substantial dose of ionizing radiation delivered to the radiosensitive thyroid gland,\(^{163}\) CT examination in children is cautioned when MRI is available.

There is still significant controversy whether MRI or CT is the preferred study to evaluate invasion of laryngeal cartilage. Before the advent of the helical CT, MRI was the preferred method.\(^{164}\) The extent of bone marrow infiltration by malignant tumors (ie, nasopharyngeal carcinoma) can be assessed with MRI of the skull base.\(^{165}\) MRI is preferred in children and can easily be extended to include the mediastinum to help evaluate congenital and neoplastic lesions. For those patients who have absolute contraindications to MRI such as pacemaker, cochlear implants, heart valve prosthesis, or aneurysmal clip, CT is a viable alternative.

Imaging studies are valuable tools in diagnosing certain causes of hoarseness in children. A plain chest radiograph will aid in the diagnosis of a mediastinal mass or foreign body. A CT scan can elucidate more detail if the initial radiography fails to show a lesion. A soft tissue radiograph of the neck can aid in the diagnosis of an infectious or allergic process.\(^{166}\) CT imaging has been the test of choice for congenital cysts, laryngeal webs, solid neoplasms, and external trauma, as it provides adequate resolution without having to sedate the patient as may be necessary for MRI. The risk of radiation must be weighed against these benefits. MRI is the better option for imaging the brain stem.\(^{166}\)

FDG-PET imaging is used increasingly to assess patients with head and neck cancer. PET scans may help identify mediastinal or pulmonary neoplasms that cause vocal fold paralysis.\(^{167}\) PET scanning is very costly, however, and may give false-positive results in patients with vocal fold paralysis. FDG activity in the normal vocal fold can be misinterpreted as a tumor.\(^{168}\)

Evidence profile for Statement 4: Imaging

- Aggregate evidence quality: Grade C, observational studies regarding the adverse events of CT and MRI; no evidence identified concerning benefits in patients with hoarseness before laryngoscopy
- Benefit: Avoid unnecessary testing; minimize cost and adverse events; maximize the diagnostic yield of CT and MRI when indicated
- Harm: Potential for delayed diagnosis
- Cost: None
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Avoidance of unnecessary testing
- Role of patient preferences: Limited
- Intentional vagueness: None
- Exclusions: None
- Policy level: Recommendation against

STATEMENT 5A. ANTI-REFLUX MEDICATION AND HOARSENESS. Clinicians should not prescribe anti-reflux medications for patients with hoarseness without signs or symptoms of gastroesophageal reflux disease (GERD). Recommendation against prescribing based on randomized trials with limitations and observational studies with a preponderance of harm over benefit.

STATEMENT 5B. ANTI-REFLUX MEDICATION AND CHRONIC LARYNGITIS. Clinicians may prescribe anti-reflux medication for patients with hoarseness and signs of chronic laryngitis. Option based on observational studies with limitations and a relative balance of benefit and harm.

Supporting Text

The primary intent of this statement is to limit widespread use of anti-reflux medications as empiric therapy for hoarseness without symptoms of GERD or laryngeal findings consistent with laryngitis, given the known adverse effects of the drugs and limited evidence of benefit. The purpose is not to limit use of anti-reflux medications in managing laryngeal inflammation, when inflammation is seen on laryngoscopy (eg, laryngitis denoted by erythema, edema, redundant tissue, and/or surface irregularities of the interarytenoid mucosa, arytenoid mucosa, posterior laryngeal mucosa, and/or vocal folds). To emphasize these dual considerations, the working group has split the statement into part A, a recommendation against empiric therapy for hoarseness, and part B, an option to use anti-reflux therapy in managing properly diagnosed laryngitis.
Anti-Reflux Medications and the Empiric Treatment of Hoarseness

The benefit of anti-reflux treatment for hoarseness in patients without symptoms of esophageal reflux (heartburn and regurgitation) or evidence for esophagitis is unclear. A Cochrane systematic review of 302 eligible studies that assess the effectiveness of anti-reflux therapy for patients with hoarseness did not identify any high-quality trials meeting the inclusion criteria. For example, a nonrandomized study on treating patients with documented reflux of stomach contents into the throat (laryngopharyngeal reflux) with twice-daily proton pump inhibitors (PPIs) could not be included in the review because hoarseness was only one component of the reflux symptom index and not an outcome separate from heartburn. One randomized, placebo-controlled trial was also not included because it did not separate hoarseness as an outcome from other laryngeal symptoms. However, the response rate for the laryngeal symptoms was 50 percent in the PPI group compared to 10 percent in the placebo group.

A randomized trial published after the Cochrane review of anti-reflux treatment for hoarseness included 145 subjects with chronic laryngeal symptoms (throat clearing, cough, globus, sore throat, or hoarseness and no cardinal GERD symptoms) and laryngoscopic evidence for laryngitis (erythema, edema, and/or surface irregularities of the interarytenoid mucosa, arytenoid mucosa, posterior laryngeal mucosa, and/or vocal folds). Subjects received either esomeprazole 40 mg twice daily or placebo for 16 weeks. There was no evidence for benefit in symptom score or laryngopharyngeal reflux health-related QOL score between the groups at the end of the study. However, this study included patients with one of many possible laryngeal symptoms and excluded patients with heartburn three or more days per week.

The benefits of anti-reflux medication for control of GERD symptoms are well documented. High-quality controlled studies demonstrate that PPIs and H2RAs (histamine-2 receptor antagonist) improve important clinical outcomes in esophageal GERD over placebo, with PPIs demonstrating superior response. Response rates for esophageal symptoms and esophagitis healing are high (approximately 80% for PPIs). In patients with hoarseness and a diagnosis of GERD, anti-reflux treatment is more likely to reduce hoarseness.

Anti-Reflux Medications and Treatment of Chronic Laryngitis

Laryngoscopy is helpful in determining whether anti-reflux treatment should be considered in managing a patient with hoarseness. Increased pharyngeal acid reflux events are more common in patients with vocal process granulomas compared to controls. Also, erythema in the vocal folds, arytenoid mucosa, and posterior commissure has improved with omeprazole treatment in patients with sore throat, throat clearing, hoarseness, and/or cough. While no differences in hoarseness improvement was seen between three months of esomeprazole vs placebo, one small randomized controlled trial found that findings of erythema, diffuse laryngeal edema, and posterior commissure hypertrophy

While generally safe for therapy shorter than two months, prolonged therapy with PPIs and H2RAs for greater than three months has been associated with significant risk. H2RAs are associated with impaired cognition in older adults. PPI use may increase the risk of bacterial gastroenteritis, specifically campylobacter and salmonella and possibly clostridium difficile. Epidemiological studies also associate PPIs with community-acquired pneumonia. Although patients with primary voice disorders may differ from those in the above mentioned studies, the treating clinician needs to consider these adverse events. Furthermore, PPIs may impair the ability of clopidogrel to inhibit platelet aggregation activity, to varying degrees depending upon the particular PPI.

Higher doses such as the twice-daily PPI therapy may carry a higher risk than once-daily therapy, and older adults may be more likely than younger adults to be harmed. Although pneumonia is more common in young children using PPIs, the prevalence of profound regurgitation and swallowing disorders is high in that population, so it is difficult to draw conclusions about the effect of the drug itself.

Use of PPI may interfere with calcium absorption and bone homeostasis. PPI use is associated with an increased risk for hip fractures in older adults. PPIs decrease vitamin B12 (cobalamin) absorption in a dose-dependent manner, and serum vitamin B12 levels may underestimate the resulting serum cobalamin deficiency. PPI use also decreases iron absorption and may cause iron deficiency anemia. Additionally, acid-suppressing drugs (both H2RAs and PPIs) were associated with an increased risk of pancreatitis in a case-controlled study, not explained by the slightly higher risk of pancreatitis seen in patients with GERD symptoms alone.

For patients with hoarseness and GERD, a trial of anti-reflux therapy may be prescribed. If hoarseness does not respond or if symptoms worsen, then pharmacological therapy should be discontinued and a search for alternative causes of hoarseness should be initiated with laryngoscopy.
showed greater improvement in the treatment arm compared to placebo.\textsuperscript{192}

More improvement in signs of laryngitis of the true vocal folds (such as erythema, edema, redundant tissue, and/or surface irregularities), posterior cricoid mucosa, and arytenoid complex were noted in patients whose laryngeal symptoms, including hoarseness, responded to four months of PPI treatment compared to nonresponders.\textsuperscript{193} Additionally, the above abnormalities of the interarytenoid mucosa and true vocal folds were predictive of improvement in laryngeal symptoms, including hoarseness.\textsuperscript{193}

Reflux of stomach contents into the laryngopharynx is an important consideration in the management of patients with laryngeal disorders. Reflux of gastric contents into the hypopharynx has been linked with subglottic stenosis.\textsuperscript{194} Case-control studies have shown that GERD may be a risk factor for laryngeal cancer,\textsuperscript{195} and that anti-reflux therapy may reduce the risk of laryngeal cancer recurrence.\textsuperscript{196} Better healing and reduced polyp recurrence after vocal fold surgery in patients taking PPIs compared to no PPIs have also been described.\textsuperscript{197}

PPI treatment may improve laryngeal lesions and objective measures of voice quality. Observational studies have demonstrated that vocal process granulomas, which may cause hoarseness, have resolved or regressed after treatment with anti-reflux medication with or without voice therapy.\textsuperscript{198} Case series also have shown improved acoustic voice measures of voice quality after one to two months of PPI therapy compared to baseline.\textsuperscript{199}

Nonetheless, there are limitations of the endoscopic laryngeal examination in diagnosing patients who may respond to PPIs. The presence of abnormal findings, such as the interarytenoid bar, has been noted in normal individuals.\textsuperscript{177} In addition, in a study of healthy volunteers not routinely using anti-reflux medication and with GERD symptoms no more than three times per month, erythema of the medial arytenoid, posterior commissure hypertrophy, and pseudosulcus were noted.\textsuperscript{200} Furthermore, the presence of specific findings depended upon the method of laryngoscopy (rigid vs flexible) and the inter-rater reliability ranged from moderate to poor depending on the specific finding.\textsuperscript{200} In a study of patients with hoarseness from a variety of diagnoses, problems with intra- and inter-rater reliability for findings of edema and erythema of the vocal folds and arytenoids have also been noted.\textsuperscript{201}

Further research exploring the sensitivity, specificity, and reliability of laryngoscopic examination findings is necessary to determine which signs are associated with treatment response with respect to hoarseness and which techniques are best to identify them.

Evidence profile for Statement 5A: Anti-reflux Medications and Hoarseness

- Aggregate evidence quality: Grade B, randomized trials with limitations showing lack of benefits for anti-reflux therapy in patients with laryngeal symptoms, including hoarseness; observational studies with inconsistent or inconclusive results; inconclusive evidence regarding the prevalence of hoarseness as the only manifestation of reflux disease

- Benefit: Avoid adverse events from unproven therapy; reduce cost; limit unnecessary treatment

- Harm: Potential withholding of therapy from patients who may benefit

- Cost: None

- Benefits-harm assessment: Preponderance of benefit over harm

- Value judgments: Acknowledgment by the working group of the controversy surrounding laryngopharyngeal reflux, and the need for further research before definitive conclusions can be drawn; desire to avoid known adverse events from anti-reflux therapy

- Intentional vagueness: None

- Patient preference: Limited

- Exclusions: Patients immediately before or after laryngeal surgery and patients with other diagnosed pathology of the larynx

- Policy level: Recommendation against

Evidence profile for Statement 5B: Anti-reflux Medication and Chronic Laryngitis

- Aggregate evidence quality: Grade C, observational studies with limitations showing benefit with laryngeal symptoms, including hoarseness, and observational studies with limitations showing improvement in signs of laryngeal inflammation

- Benefit: Improved outcomes, promote resolution of laryngitis

- Harm: Adverse events related to anti-reflux medications

- Cost: Direct cost of medications

- Benefits-harm assessment: Relative balance of benefit and harm

- Value judgments: Although the topic is controversial, the working group acknowledges the potential role of anti-reflux therapy in patients with signs of chronic laryngitis and recognizes that these patients may differ from those with an empiric diagnosis of hoarseness (dysphonia) without laryngeal examination

- Patient preference: Substantial role for shared decision making

- Intentional vagueness: None

- Exclusions: None

- Policy level: Option

STATEMENT 6. CORTICOSTEROID THERAPY: Clinicians should not routinely prescribe oral corticosteroids to treat hoarseness. Recommendation against prescribing based on randomized trials showing adverse events and absence of clinical trials demonstrating benefits with a preponderance of harm over benefit for steroid use.
Supporting Text

Oral steroids are commonly prescribed for hoarseness and acute laryngitis, despite an overwhelming lack of supporting data of efficacy. A systematic search of MEDLINE, CINAHL, EMBASE, and the Cochrane Library revealed no studies supporting the use of corticosteroids as empiric therapy for hoarseness except in special circumstances as discussed below.

Although hoarseness is often attributed to acute inflammation of the larynx, the temptation to prescribe systemic or inhaled steroids for acute or chronic hoarseness or laryngitis should be avoided because of the potential for significant and serious side effects. Side effects from corticosteroids can occur with short- or long-term use, although the frequency increases with longer durations of therapy (Table 8). Additionally, there are many reports implicating long-term inhaled steroid use as a cause of hoarseness.

Despite these side effects, there are some indications for steroid use in specific disease entities and patients. A specific and accurate diagnosis should be achieved, however, before beginning this therapy. The literature does support steroid use for recurrent croup with associated laryngitis in pediatric patients and allergic laryngitis. Patients with chronic laryngitis and dysphonia may have environmental allergy. In limited cases, systemic steroids have been reported to provide quick relief from allergic laryngitis for performers. While these are not high-quality trials, they suggest a possible role for steroids in these selected patient populations. Additionally, in patients acutely dependent on their voice, the balance of benefit and harm may be shifted. The length of treatment for allergy-associated dysphonia with steroids has not been well defined in the literature.

Pediatric patients with croup and other associated symptoms such as hoarseness had better outcomes when treated with systemic steroids. Steroids should also be considered in patients with airway compromise to decrease edema and inflammation. An appropriate evaluation and determination of the cause of the airway compromise is required prior to starting the steroid therapy. Steroids are also helpful in some autoimmune disorders involving the larynx such as systemic lupus erythematosus, sarcoidosis, and Wegener granulomatosis.

Evidence profile for Statement 6: Corticosteroid Therapy

- Aggregate evidence quality: Grade B, randomized trials showing increased incidence of adverse events associated with orally administered steroids; absence of clinical trials demonstrating any benefit of steroid treatment on outcomes
- Benefit: Avoid potential adverse events associated with unproven therapy
- Harm: None
- Cost: None
- Benefits-harm assessment: Preponderance of harm over benefit for steroid use
- Value judgments: Avoid adverse events of ineffective or unproven therapy
- Role of patient preferences: Some; there is a role for shared decision making in weighing the harms of steroids against the potential yet unproven benefit in specific circumstances (ie, professional or avocation voice use and acute laryngitis)
- Intentional vagueness: Use of the word “routine” to acknowledge there may be specific situations, based on laryngoscopy results or other associated conditions, that may justify steroid use on an individualized basis
- Exclusions: None
- Policy level: Recommendation against

STATEMENT 7. ANTIMICROBIAL THERAPY: Clinicians should not routinely prescribe antibiotics to treat hoarseness. Strong recommendation against prescribing based on systematic reviews and randomized trials showing ineffectiveness of antibiotic therapy and a preponderance of harm over benefit.

Supporting Text

Hoarseness in most patients is caused by acute laryngitis or a viral upper respiratory infection, neither of which are bacterial infections. Since antimicrobials are only effective for bacterial infections, their routine, empiric use in treating patients with hoarseness is unwarranted.

Upper respiratory infections often produce symptoms of sore throat and hoarseness, which may alter voice quality and function. Acute upper respiratory infections caused by parainfluenza, rhinovirus, influenza, and adenovirus have been linked to laryngitis. Furthermore, acute laryngitis is self-limited, with patients having improvement in 7 to 10 days undergoing placebo treatment. A Cochrane review examining the role of antibiotics in acute laryngitis in patients with airway compromise to decrease edema and inflammation. An appropriate evaluation and determination of the cause of the airway compromise is required prior to starting the steroid therapy. Steroids are also helpful in some autoimmune disorders involving the larynx such as systemic lupus erythematosus, sarcoidosis, and Wegener granulomatosis.

Evidence profile for Statement 6: Corticosteroid Therapy

- Aggregate evidence quality: Grade B, randomized trials showing increased incidence of adverse events associated with orally administered steroids; absence of clinical trials demonstrating any benefit of steroid treatment on outcomes
- Benefit: Avoid potential adverse events associated with unproven therapy
- Harm: None
- Cost: None
- Benefits-harm assessment: Preponderance of harm over benefit for steroid use
- Value judgments: Avoid adverse events of ineffective or unproven therapy
- Role of patient preferences: Some; there is a role for shared decision making in weighing the harms of steroids against the potential yet unproven benefit in specific circumstances (ie, professional or avocation voice use and acute laryngitis)
- Intentional vagueness: Use of the word “routine” to acknowledge there may be specific situations, based on laryngoscopy results or other associated conditions, that may justify steroid use on an individualized basis
- Exclusions: None
- Policy level: Recommendation against

STATEMENT 7. ANTIMICROBIAL THERAPY: Clinicians should not routinely prescribe antibiotics to treat hoarseness. Strong recommendation against prescribing based on systematic reviews and randomized trials showing ineffectiveness of antibiotic therapy and a preponderance of harm over benefit.

Supporting Text

Hoarseness in most patients is caused by acute laryngitis or a viral upper respiratory infection, neither of which are bacterial infections. Since antimicrobials are only effective for bacterial infections, their routine, empiric use in treating patients with hoarseness is unwarranted.

Upper respiratory infections often produce symptoms of sore throat and hoarseness, which may alter voice quality and function. Acute upper respiratory infections caused by parainfluenza, rhinovirus, influenza, and adenovirus have been linked to laryngitis. Furthermore, acute laryngitis is self-limited, with patients having improvement in 7 to 10 days undergoing placebo treatment. A Cochrane review examining the role of antibiotics in acute laryngitis in
adults found only two studies meeting the inclusion criteria and no benefit of either penicillin or erythromycin.227 Similar findings of no benefit for antibiotics in acute upper respiratory tract infections in adults and children were noted in another Cochrane review.228

The potential harm from antibiotics must also be considered. Common adverse effects include rash, abdominal pain, diarrhea, and vomiting and are more common in patients receiving antibiotics compared to placebo.228,229 Interactions may also occur between specific antibiotics and other medications.230

In addition to negative consequences from antibiotic use on an individual level, important societal implications exist. Over-prescribing antibiotics may contribute to bacterial resistance to antibiotics. Compared to the years 2001 to 2003, more methicillin-resistant Staphylococcus aureus has been isolated in acute and chronic maxillary sinusitis in the period 2004 to 2006.231 Furthermore, antibiotic treatment costs for infectious diseases, such as community-acquired pneumonia, were 33 percent higher in communities with high antibiotic resistance rates.232 Thus, overuse of antibiotics for hoarseness has negative potential results for both the individual and the general population.

While uncommon, antibiotics may be appropriate in select rare causes of hoarseness. Laryngeal tuberculosis in renal transplant patients and in patients with human immunodeficiency virus (HIV) have been reported.233,234 An atypical mycobacterial laryngeal infection has also been reported in a patient on inhaled steroids.235 Although immunosuppression may predispose to a bacterial laryngitis, laryngeal tuberculosis has also been documented in patients without HIV and laryngeal actinomycosis has occurred in an immunocompetent patient.236-238 A laryngeal mass or ulcer is often present in these infectious etiologies, requiring a high index of suspicion for malignancy. For immunocompromised patients with hoarseness, laryngoscopy is warranted and biopsy for diagnosis should be performed, if indicated.

Antibiotics may also be warranted in patients with hoarseness secondary to other bacterial infections. Recently, community outbreaks of pertussis attributed to waning immunity in adolescents and adults have been reported.239 Among adults with pertussis, multiple symptoms have been reported including hoarseness in 18 percent.240 Among children, bacterial tracheitis, often from Staphylococcus aureus, may be associated with crusting and may cause severe upper airway infection and present with multiple symptoms such as cough, stridor, increased work of breathing, and hoarseness.241

Evidence profile for Statement 7: Antimicrobial Therapy

- Benefit: Avoidance of ineffective therapy with documented adverse events
- Harm: Potential for failing to treat bacterial, fungal, or mycobacterial causes of hoarseness
- Cost: None
- Benefit-harm assessment: Preponderance of harm over benefit if antibiotics are prescribed
- Values: Importance of limiting antimicrobial therapy to treating bacterial infections
- Role of patient preferences: None
- Intentional vagueness: The word “routine” is used in the boldface statement to discourage empiric therapy yet to acknowledge there are occasional circumstances where antibiotic use may be appropriate
- Exclusions: Patients with hoarseness caused by bacterial infection
- Policy level: Strong recommendation against

STATEMENT 8A. LARYNGOSCOPY PRIOR TO VOICE THERAPY: Clinicians should visualize the larynx before prescribing voice therapy and document/communicate the results to the speech-language pathologist. Recommendation based on observational studies showing benefit and a preponderance of benefit over harm.

STATEMENT 8B. ADVOCATING FOR VOICE THERAPY: Clinicians should advocate voice therapy for patients diagnosed with hoarseness (dysphonia) that reduces voice-related QOL. Strong recommendation based on systematic reviews and randomized trials with a preponderance of benefit over harm.

Laryngoscopy Prior to Voice Therapy

Voice therapy is a well-established treatment modality for some voice disorders, but therapy should not begin until a diagnosis is made. Failure to visualize the larynx and establish a diagnosis can lead to inappropriate therapy or delay in diagnosis of pathology not amenable to voice therapy.127,128 Additionally, the information gained by laryngoscopy may help in designing an optimal therapy regimen.

Evidence-based guidelines from the Royal College of Speech and Language Therapists mandate that a patient be evaluated by an ENT surgeon (otolaryngologist) prior to voice therapy, or simultaneously with the speech-language pathologist (SLP).242 While the guideline does not explicitly refer to laryngoscopy, it states that the “evaluation is needed to identify disease, assess structure and contribute to the assessment of function,” and laryngoscopy is the primary tool for this assessment. The American Speech-Language-Hearing Association (ASHA) acknowledges these guidelines and specifies in their own practice policy that the clinical process for voice evaluation entails that “all patients/clients with voice disorders are examined by a phy-
An SLP trained in visual imaging may examine the larynx for the purpose of evaluating vocal function and planning an appropriate therapy program for the voice disorder. In some practices that care for voice disorders, the SLP works with an otolaryngologist in the multidisciplinary treatment of voice disorders and may perform the examination, which is then reviewed by the otolaryngologist. Examination or review by the otolaryngologist will ensure that diagnoses not treatable with voice therapy, such as laryngeal cancer or papilloma, are managed appropriately. This recommendation is consistent with published guidelines of ASHA. There are also published guidelines outlining the knowledge, skills, and training necessary for the use of videostroboscopy by the SLP. The guideline panel agreed that performance of stroboscopic evaluation by the SLP with diagnosis by the laryngologist may be time saving in certain settings.

There is significant evidence for the usefulness of laryngoscopy, specifically videostroboscopy, in planning voice therapy and in documenting the effectiveness of voice therapy in the remediation of vocal lesions. According to the guideline panel, the results of the laryngeal examination should be documented and communicated to the SLP who will conduct voice therapy prior to the initiation of medical or surgical treatment. The report should include a detailed diagnosis/description of the laryngeal pathology and brief history of the problem. Visual images of the pathology may also help in treatment planning.

**Advocating for Voice Therapy**

Clinicians should advocate voice therapy by making patients aware that this is an effective intervention for hoarseness and providing brochures or sources of further information (see Appendix, “Frequently Asked Questions About Voice Therapy”). The clinician can document advocacy in a chart note by documenting a discussion of speech therapy, by recording educational materials dispersed to the patient, by recording that the patient was supplied with a website, or by documenting referral to an SLP.

Clinicians have several choices for managing hoarseness including observation, medical therapy, surgical therapy, voice therapy, or a combination of these approaches. Voice therapy, provided by a certified SLP, attends to the behavioral issues contributing to hoarseness. Voice therapy is effective for hoarseness across the lifespan from children to older adults. Children younger than two years, however, may not be able to participate fully and effectively in many forms of voice therapy. Education and counseling may be of benefit to the family.

Several approaches to voice therapy for treating hoarseness have been identified in the literature. Hygienic approaches focus on eliminating behaviors considered to be harmful to the vocal mechanism. Symptomatic approaches target the direct modification of aberrant features of pitch, loudness, and quality. Physiologic methods approach treatment holistically, as they work to retrain and rebalance the subsystems of respiration, phonation, and resonance.

A systematic review of the efficacy literature by Thomas and Stemple revealed various levels of support for the three approaches. The efficacy of physiologic approaches was well supported by randomized and other controlled trials. Hygiene approaches showed mixed results in relatively well-designed controlled trials. Furthermore, mostly observational studies were found supporting symptomatic approaches.

Hoarseness may be recurring or situational. Recurring hoarseness refers to hoarseness that is intermittent, as might be the case with functional voice disorders (characterized by abnormal voice quality not caused by anatomic changes to the larynx). Situational hoarseness refers to hoarseness that occurs only during certain situations, such as lecturing or singing. Voice therapy is often beneficial when combined with other hoarseness treatment approaches, including preoperative and postoperative therapy, or in combination with certain medical treatments (ie, allergy management, asthma therapy, anti-reflux therapy).

Specific voice therapy for treating hoarseness is effective in Parkinson disease and paradoxical vocal fold dysfunction/ cough. Voice therapy for treating spasmodic dysphonia is useful as an adjunct to botulinum toxin. Voice therapy alone for treating spasmodic dysphonia remains controversial and not well supported.

The interdisciplinary treatment of hoarseness may also include contributions from singing teachers, acting voice coaches, and other medical disciplines in conjunction with voice therapy provided by an SLP.

**Evidence profile for Statement 8A: Visualizing the Larynx**

- Aggregate evidence quality: Grade C, observational studies of the benefit of laryngoscopy for voice therapy
- Benefit: Avoid delay in diagnosing laryngeal conditions not treatable with voice therapy, optimize voice therapy by allowing targeted therapy
- Harm: Delay in initiation of voice therapy
- Cost: Cost of the laryngoscopy and associated clinician visit
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: To ensure no delay in identifying pathology not treatable with voice therapy, SLPs cannot initiate therapy prior to visualization of the larynx by a clinician
- Intentional vagueness: None
- Role of patient preferences: Minimal
- Exclusions: None
- Policy level: Recommendation

**Evidence profile for Statement 8B: Advocating for Voice Therapy**

- Aggregate evidence quality: Grade A, randomized controlled trials and systematic reviews
STATEMENT 9. SURGERY: Clinicians should advocate for surgery as a therapeutic option in patients with hoarseness with suspected: 1) laryngeal malignancy, 2) benign laryngeal soft tissue lesions, or 3) glottic insufficiency. Recommendation based on observational studies demonstrating a benefit of surgery in these conditions and a preponderance of benefit over harm.

Supporting Text
Clinicians should be aware that surgery may be indicated for certain conditions that cause hoarseness. Surgery is not the primary treatment for the majority of hoarse patients and is targeted at specific pathologies. Conditions with surgical options can be categorized into four broad groups: 1) suspected malignancy, 2) benign soft tissue lesions, 3) glottic insufficiency, and 4) laryngeal dystonia.

Suspected malignancy. Characteristics leading to suspicion of malignancy are described above (see laryngoscopy). Hoarseness may be the presenting sign in malignancy of the upper aerodigestive tract. Malignancy was observed to be the cause of hoarseness in 28 percent of patients over age 60 after patients with self-limited disease were excluded. 

Surgical biopsy with histopathologic evaluation is necessary to confirm the diagnosis of malignancy in upper airway lesions. Highly suspicious lesions with increased vasculature, ulceration, or exophytic growth require prompt biopsy. A trial of conservative therapy with avoidance of irritants may be employed prior to biopsy for superficial white lesions on otherwise mobile vocal folds.

Benign soft tissue lesions. The production of normal voice depends, in part, on intact and functional vocal fold mucosal and submucosal layers. Some benign lesions of the vocal fold mucosa and submucosa result in aberrant vibratory patterns. Specific benign lesions of the vocal folds include vocal “singer’s” nodules, polypoid degeneration (Reinke’s edema), hemorrhagic or fibrotic polyps, ectatic or dilated vessels, scar or sulcus vocalis, cysts (epidermal inclusion and mucous retention), and vocal process granulomas. Another benign lesion, laryngeal stenosis, may not affect the vocal folds directly, but may affect the voice.

A trial of conservative management is typically instituted prior to surgical intervention for most pathologies and may obviate the need for surgery. Many benign soft tissue lesions of the vocal folds are self-limited or reversible. The conservative management strategy indicated depends on the likely underlying etiology but may include voice therapy or rest, smoking cessation, and anti-reflux therapy. In a retrospective study of 26 patients with hoarseness secondary to true vocal fold nodules, 80 percent of patients achieved normal or near-normal voice with voice therapy alone. Furthermore, failure to address underlying etiologies may lead to frequent postsurgical recurrence of some lesions, especially granulomas. Surgery is reserved for benign vocal fold lesions when a satisfactory voice result cannot be achieved with conservative management and the voice may be improved with surgical intervention.

Surgery may improve both subjective voice-related QOL and objective vocal parameters in patients with hoarseness secondary to benign vocal fold lesions. A retrospective review of 42 patients with benign vocal fold lesions demonstrated significant improvement in voice-related QOL and acoustic parameters following surgery. Multiple studies of surgical treatment of ectatic vessels, polypoid degeneration (Reinke’s edema), nodules, and polyps all showed significant benefit. Surgery is necessary in the management of recurrent respiratory papilloma (RRP), a benign but aggressive neoplasm of the upper airway more commonly seen in children. Human papillomavirus subtypes 6 and 11 are the most common cause. Surgical removal with standard laryngeal instruments, microdebrider, or laser can prevent airway obstruction and is effective in reducing the symptoms of hoarseness, but it is unlikely to be curative since viral particles may be present in adjacent normal-appearing mucosa. Additionally, certain lesions may be amenable to treatment in the office under topical anesthesia using advanced laryngoscopic techniques.

Type of instrumentation does not seem to affect outcome when comparing laser to cold dissection. The surgical method used is less important than the experience and skill of the operating surgeon in obtaining satisfactory vocal outcomes in the surgical treatment of benign vocal fold lesions. While bleeding, scarring, airway compromise, and poor voice outcomes are all possible risks of surgery, no serious surgery-related complications were noted in any case series or trial.

Glottic insufficiency. A normal voice is created by two mobile vocal folds making contact in the midline space of the larynx (glottis), thereby creating the vibratory sound waves perceived as voice. Glottic insufficiency due to vocal fold weakness (eg, paralysis or paresis) or vocal fold soft tissue
defects often result in a weak, breathy hoarseness with poor cough and reduced airway protection during swallow. Details of characteristics leading to suspicion of glottic insufficiency are described above (see laryngoscopy section). Glottic insufficiency is especially common in older adults, in whom up to 30 percent of hoarseness was due to vocal fold changes after self-limited causes were excluded.\textsuperscript{91,92}

Surgical management of glottic insufficiency is primarily through static positioning of the weak vocal fold in the midline glottis (medialization laryngoplasty). Static medialization of the vocal folds can be achieved either by injection of a bulking agent into the vocal fold (injection laryngoplasty) or external medialization with open surgery (laryngeal framework surgery), or a combination of the two. Injection laryngoplasty can be safely performed in the office under local anesthesia or in the operating room under general anesthesia.\textsuperscript{274} While no randomized trials were found directly comparing injection laryngoplasty to laryngeal framework surgery, observational studies show comparable objective and subjective improvement in voice.\textsuperscript{275}

Resorbable, temporary injectable implants are often used to provide vocal rehabilitation while allowing time for neural recovery or full denervation atrophy of the vocal musculature prior to permanent medialization. In a randomized controlled trial of patients with glottic insufficiency comparing bovine collagen to hyaluronic acid gel, 42 patients with sufficient follow-up demonstrated significantly improved subjective and objective vocal parameters.\textsuperscript{276} There were no complications noted in this study, but 26 percent of patients required repeat injection over 24 months of observation. Additional retrospective series of temporary injectables demonstrated subjective and objective hoarseness reduction in 80 percent to 95 percent of treated patients.\textsuperscript{277-280} In addition, there are limited data that collagens or lyophilized dermis injections can provide adequate vocal rehabilitation of pediatric patients.\textsuperscript{281}

Injection laryngoplasty with stable, semi-permanent implants is used when vocal recovery is unlikely.\textsuperscript{274} Prospective trials of both silicone and hydroxyapatite paste have demonstrated significant improvement in validated voice QOL measures in 94 percent to 100 percent of patients without significant complications after six-month follow-up.\textsuperscript{282,283} Since there are several suitable alternatives, the use of polytetrafluoroethylene as a permanent injectable implant is not recommended due to its association with foreign body granulomas that can result in voice deterioration and airway compromise.\textsuperscript{284,285}

External medialization laryngoplasty by open laryngeal framework surgery, also known as type I thyroplasty, has demonstrated hoarseness reduction using a variety of implants made of Silastic, titanium, Gore-tex, and hydroxyapatite.\textsuperscript{286-288} When analyzed by trained, blinded listeners, the voices of 15 patients who underwent external laryngoplasty were indistinguishable from normal controls in loudness and pitch but had higher levels of strain and breathiness.\textsuperscript{289} In a retrospective study of 117 patients with glottic insufficiency, patients who received external laryngoplasty demonstrated better symptom resolution compared to patients receiving voice therapy alone.\textsuperscript{290}

Arytenoid adduction is an additional laryngeal framework procedure used to rotate the vocal process of the arytenoid medially in patients with large posterior glottic gaps. A meta-analysis of three studies found no clear benefit if arytenoid adduction is added to external laryngoplasty compared to external laryngoplasty alone.\textsuperscript{291} External laryngoplasty has been performed successfully in children but may be technically more challenging due to the variable position of the pediatric vocal fold.\textsuperscript{292,293}

**Laryngeal dystonia.** Surgical treatment for laryngeal dystonia, or adductor spasmodic dysphonia, is infrequently performed due to the widespread acceptance of botulinum toxin as the first-line treatment for this disorder. Attempts to control the disorder with recurrent laryngeal nerve section resulted in inconsistent, often temporary improvement, with recurrence in up to 80 percent of cases.\textsuperscript{294-297} A single, retrospective study of laryngeal dystonia patients treated with bilateral division of the adductor branch of the recurrent laryngeal nerve followed by ansa cervicalis reinnervation demonstrated resolution of symptoms in 19 of 21 patients followed for at least 12 months.\textsuperscript{298}

**Evidence profile for Statement 9: Surgery**

- **Aggregate evidence quality:** Grade B, in support of surgery to reduce hoarseness and improve voice quality in selected patients based on observational studies overwhelmingly demonstrating the benefit of surgery
- **Benefit:** Potential for improved voice outcomes in carefully selected patients
- **Harm:** None
- **Cost:** None
- **Benefits-harm assessment:** Preponderance of benefit over harm
- **Value judgments:** Surgical options for treating hoarseness are not always recognized; selected patients with hoarseness may benefit from newer, less invasive technologies
- **Role of patient preferences:** Limited
- **Intentional vagueness:** None
- **Exclusions:** None
- **Policy level:** Recommendation

**STATEMENT 10. BOTULINUM TOXIN: Clinicians should prescribe, or refer the patient to a clinician who can prescribe, botulinum toxin injections for the treatment of hoarseness caused by spasmodic dysphonia.** Recommendation based on randomized controlled trials with minor limitations and preponderance of benefit over harm.

**Supporting Text**

Spasmodic dysphonia (SD) is a focal dystonia most commonly characterized by a strained, strangled voice.\textsuperscript{299} Pa-
tients demonstrate increased tone or tremor of intralaryngeal muscle groups responsible for either opening (abductor SD) or closing (adductor SD) of the vocal folds. Intramuscular injection of botulinum toxin into the affected muscles causes transient, nondestructive flaccid paralysis of these muscles by inhibiting the release of acetylcholine from nerve terminals, thus reducing the spasm.\textsuperscript{300} SD is a disorder of the central nervous system that cannot be cured by botulinum toxin.\textsuperscript{301} but excellent symptom control is possible for 3 to 6 months with treatment.\textsuperscript{302} Treatment can be performed on awake, ambulatory patients with minimal discomfort.\textsuperscript{303} While not currently FDA approved for SD, a large body of evidence supports the efficacy of botulinum toxin (primarily botulinum toxin A) for treating adductor spasmodic dysphonia. Multiple double-blind, randomized, placebo-controlled trials of botulinum toxin for adductor spasmodic dysphonia using both self-assessment and expert listeners found improved voice in patients treated with botulinum toxin injections.\textsuperscript{304,305} Botulinum toxin treatment has also been shown to improve self-perceived dysphonia, mental health, and social functioning.\textsuperscript{306} A meta-analysis concluded that botulinum toxin treatment of spasmodic dysphonia results in “moderate overall improvement;” however, it notes concerns of methodological limitations and lack of standardization in assessment of botulinum toxin efficacy and recommends caution when making inferences regarding treatment benefit.\textsuperscript{307} Despite these limitations, among laryngologists, botulinum toxin is considered the “treatment of choice” for adductor SD.\textsuperscript{301,302,307}

Botulinum toxin has been used for other disorders of excessive or inappropriate muscular contraction.\textsuperscript{300} There are limited reports addressing the use of botulinum toxin for spastic dysarthria, nerve-section failure, anterior commissure release, adductor breathing dystonia, abductor spasmodic dysphonia, ventricular dysphonia (also called dysphonia plica ventricularis), and voice tremor.\textsuperscript{280,281,289-293}

Botulinum toxin injections have a good safety record. Blitzer et al reported their 13-year experience in 901 patients who underwent 6300 injections; adverse effects included “mild breathlessness and coughing on fluids” in the adductor SD patients, and “mild stridor” in abductor SD patients.\textsuperscript{308} The most common adverse effects of botulinum toxin injection are breathlessness and dysphagia, including choking on fluids.\textsuperscript{309-313} Risk of harm may be greater with inexperienced users.\textsuperscript{301} Post-treatment dysphagia appears more common in patients with dysphagia prior to injection.\textsuperscript{314} Exertional wheezing, exercise intolerance, and stridor were reported more commonly in patients with abductor SD.\textsuperscript{308,315}

Adverse events may result from diffusion of drug from the target muscle to adjacent muscles (this has been added as a “boxed warning” by the FDA).\textsuperscript{300} Adjusting the dose, distribution, and timing of injections may decrease the frequency of adverse events.\textsuperscript{313,316} Bleeding is rare, and vocal fold edema has only been documented in a single patient receiving saline as a placebo.\textsuperscript{304} Reports of sensations of burning, tickling, irritation of the larynx or throat, excessive thick secretions, and dryness have also occurred.\textsuperscript{317} Systemic effects are rare, with only two reports of generalized botulism-like syndromes and one report of possible precipitation of biliary colic.\textsuperscript{300} Acquired resistance to botulinum toxin can occur.

Evidence profile for Statement 10: Botulinum Toxin

- Aggregate evidence quality: Grade B, few controlled trials, diagnostic studies with minor limitations, and overwhelmingly consistent evidence from observational studies
- Benefit: Improved voice quality and voice-related QOL
- Harm: Risk of aspiration and airway obstruction
- Cost: Direct costs of treatment, time off work, and indirect costs of repeated treatments
- Benefit-harm assessment: Preponderance of benefit over harm
- Value judgments: Botulinum toxin is beneficial despite the potential need for repeated treatments considering the lack of other effective interventions for spasmodic dysphonia
- Role of patient preferences: Patient must be comfortable with FDA off-label use of botulinum toxin. While strong evidence supports its use, botulinum toxin injection is an invasive therapy offering only temporarily relief of a non-life-threatening condition. Patients may reasonably elect not to have it performed
- Intentional vagueness: None
- Exclusions: None
- Policy level: Recommendation

STATEMENT 11. PREVENTION: Clinicians may educate/counsel patients with hoarseness about control/preventive measures. Option based on observational studies and small randomized trials of poor quality.

Supporting Text

The risk of hoarseness may be diminished by preventive measures such as hydration, avoidance of irritants, voice training, and amplification. Currently available studies evaluating these measures are limited in scope and quality. There is some evidence that adequate hydration may decrease the risk of hoarseness. In a study of 422 teachers, absence of water intake was associated with a 60 percent higher risk of hoarseness. Objective findings of hoarseness and vocal fold thickness were found in patients with post-dialysis dehydration.\textsuperscript{320} An observational study of amateur singers demonstrated less vocal fatigue with hydration and periods of voice rest.\textsuperscript{321} Phonatory effort may also be decreased by adequate hydration.\textsuperscript{57} There are very limited data suggesting that amplification during heavy voice use may sustain voice quality.\textsuperscript{322}

A 2007 Cochrane review evaluated the effectiveness of interventions designed to prevent or reduce voice disor-
school teachers. The review did not find sufficient evidence to substantiate the use of voice training as a preventive measure. The two randomized controlled studies included in the review had several methodological problems related to sample size, design, and outcome measures.

Despite limited evidence in the literature, the panel concurred that avoidance of tobacco smoke (primary or secondhand) was beneficial to decrease the risk of hoarseness. There is also observational evidence from a single study of 10 symptomatic rescue workers at the World Trade Center disaster site that irritants such as chemicals, smoke particulates, and pollution can increase the likelihood of developing hoarseness.

Evidence profile for Statement 11: Prevention
- Aggregate evidence quality: Grade C, evidence based on several observational studies and a few small randomized trials of poor quality
- Benefit: Possible prevention of hoarseness in high-risk persons
- Harm: None
- Cost: Cost of vocal training sessions
- Value judgments-harm assessment: Preponderance of benefit over harm

RESEARCH NEEDS

While there is a body of literature from which these guidelines were drawn, significant gaps in our knowledge about hoarseness and its management remain. The guideline committee identified several areas where further research would improve the ability of clinicians to manage hoarse patients optimally.

Hoarseness is known to be common, but the prevalence of hoarseness in certain populations such as children is not well known. Additionally, the prevalence of specific etiologies of hoarseness is not known. Descriptive statistics would help to shape thinking on distribution of resources, levels of care, and cost mandates.

Although a strong intuitive sense of the natural history of many voice disorders exists among practitioners, data are lacking. This dearth of information makes judgments related to the value of observation vs intervention challenging. Some of the entities that might benefit from study include viral laryngitis, fungal laryngitis, inhaler-related laryngitis, voice abuse, reflux, and benign lesions (ie, nodules, polyps, cysts, etc). A better understanding of the natural history of these disorders could be obtained through prospective observational studies and will have clear implications for the necessity and timing of behavioral, medical, and surgical interventions.

Prospective studies on the value of steroids and antibiotics for infectious laryngitis are also lacking. Given the known potential harms from these medications, prospective studies examining the benefits relative to placebo are warranted.
Reflux laryngitis is a very common diagnosis with much controversy surrounding it. While there are a number of studies looking at the use of anti-reflux therapy for chronic laryngitis, the vast majority have severe limitations. Well-conducted and controlled studies of anti-reflux therapy for patients with hoarseness and for patients with signs of laryngeal inflammation would help to establish the value of these medications. Further clarification of which hoarse patients may benefit from reflux treatment would help to optimize outcomes and minimize costs and potential side effects. Future studies may benefit from strict inclusion criteria and specific investigation of the outcome of hoarseness (dysphonia) control.

Although ancillary testing such as radiographic imaging is often performed to assist in diagnosing the underlying cause of hoarseness, the role of these tests has not been clearly defined. Their usefulness as screening tools is unclear and the cost effectiveness of their use has not been established.

Despite data that strongly demonstrate better survival and local control rates in early-stage laryngeal cancers, the improvement of laryngeal cancer outcomes through early screening has not been shown. Study of the effect of early screening and diagnosis is warranted.

Voice therapy has been shown to provide short-term benefit for hoarse patients, but long-term efficacy has not been shown. Also, the relative harm of voice therapy has not been studied (eg, lost work time, anxiety), making the risk/benefit ratio difficult to evaluate.

As office-based procedures are developed to manage causes of hoarseness previously treated in the operating room, comparative studies on the safety and efficacy of office-based procedures relative to those performed under general anesthesia are needed (eg, injection vs open thyroplasty).

DISCLAIMER

As medical knowledge expands and technology advances, clinical indicators and guidelines are promoted as conditional and provisional proposals of what is recommended under specific conditions, but they are not absolute. Guidelines are not mandates and do not and should not purport to be a legal standard of care. The responsible physician, in light of all the circumstances presented by the individual patient, must determine the appropriate treatment. Adherence to these guidelines will not ensure successful patient outcomes in every situation. The American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS) emphasizes that these clinical guidelines should not be deemed to include all proper treatment decisions or methods of care, or to exclude other treatment decisions or methods of care reasonably directed to obtaining the same results.

ACKNOWLEDGEMENT

We gratefully acknowledge the support provided by Kristine Schulz, MPH, from the AAO-HNS Foundation.

AUTHOR INFORMATION

From Virginia Mason Medical Center (Dr Schwartz), Seattle, WA; Duke University School of Medicine (Dr Cohen), Durham, NC; University of Wisconsin School of Medicine and Public Health (Drs Dailey and McMurray), Madison, WI; SUNY Downstate Medical College and Long Island College Hospital (Dr Rosenfeld), Brooklyn, NY; Alfred I duPont Hospital for Children (Dr Deutsch), Wilmington, DE; Medical University of South Carolina (Dr Gillespie), Charleston, SC; Columbia University College of Physicians and Surgeons (Dr Granieri), New York, NY; Emory Voice Center (Dr Hapner), Atlanta, GA; All About Children Pediatric Partners, P.C. (Dr Kimball), Reading, PA; Wayne State University (Dr Krouse), Detroit, MI; University of Massachusetts School of Medicine (Dr Medina), Uxbridge, MA; US Army Training and Doctrine Command (Dr O’Brien), Fort Monroe, VA; Henry Ford Hospital (Dr Ouellette), Detroit, MI; Cleveland Clinic (Dr Messinger-Rapport), Cleveland, OH; Henry Ford Medical Group (Dr Stachler), Detroit, MI; University of Arkansas for Medical Sciences (Dr Strode), Little Rock, AR; Mayo Clinic (Dr Thompson), Rochester, MN; University of Kentucky College of Health Sciences (Dr Stemple), Lexington, KY; Cincinnati Children’s Hospital Medical Center (Dr Willging), Cincinnati, OH; The TMI Association (Ms Cowley), Milwaukee, WI; Westminster Choir College of Rider University (Dr McCoy), Princeton, NJ; Metropolitan Medical Center (Dr Bernad), Washington, DC; and The American Academy of Otolaryngology—Head and Neck Surgery (Mr Patel), Alexandria, VA.

Corresponding author: Seth R. Schwartz, MD, MPH, Virginia Mason Medical Center, 1100 Ninth Avenue, MS X10-ON, PO Box 900, Seattle, WA 98111.

E-mail address: seth.schwartz@vmmc.org.

AUTHOR CONTRIBUTIONS

Seth R. Schwartz, writer, chair; Seth M. Cohen, writer, assistant chair; Seth H. Dailey, writer, assistant chair; Richard M. Rosenfeld, writer, consultant; Ellen S. Deutsch, writer; M. Boyd Gillespie, writer; Evelyn Granieri, writer; Edie R. Hapner, writer; C. Eve Kimball, writer; Helene J. Krouse, writer; J. Scott McMurray, writer; Safdar Medina, writer; Karen O’Brien, writer; Daniel R. Ouellette, writer; Barbara J. Messinger-Rapport, writer; Robert J. Stachler, writer; Steven Strode, writer; Dana M. Thompson, writer; Joseph C. Stemple, writer; J. Paul Willging, writer; Terrie Cowley, writer; Scott McCoy, writer; Peter G. Bernad, writer; Miles M. Patel, writer.

DISCLOSURES

Competing interests: Seth M. Cohen, TAP Pharmaceuticals: patient education grant; Seth H. Dailey, Bioform: one time consultant (2008); Ellen S. Deutsch, Kramer Patient Education: reviewer; M. Boyd Gillespie, Restore Medical (Medtronic): research support; study site for Pillar-CPAP study; Helene J. Krouse, Alcon: Speaker’s Bureau; Schering-Plough: grant funding; Daniel R. Ouellette, Pfizer: Speaker’s Bureau; Boehringer Ingelheim: Speaker’s Bureau; Barbara J. Messinger-Rapport, Forest: speaker; Novartis: speaker; Robert J. Stachler, GlaxoSmithKline: consultant; Steven Strode, Central AR Veterans Healthcare System: employee; American Academy of Family Physicians: delegate; commission member; E.Doc America: for-profit health information...
service; Joseph C. Stemple, KayPentax: product grant; Plural Publishing: author royalties and Speaker’s Bureau; J. Paul Willing, expert witness: hourly fee to review medical records and comment on quality of care–pediatric ENT-related.

Sponsorships: Sponsor and funding source: American Academy of Otolaryngology—Head and Neck Surgery. The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the AAO-HNS Foundation. Members of the AAO-HNS and other allied health/physician organizations were involved with the study design and conduct; collection, analysis, and interpretation of the data; and writing or approval of the manuscript.

REFERENCES

Schwartz et al  Clinical practice guideline: Hoarseness (Dysphonia)  S25


286. Schneider B, Bigenzahn W, End A, et al. External vocal fold medi-
alization in patients with recurrent nerve paralysis following cardio-

287. Zeitels SM, Mauiri M, Dailey SH. Medialization laryngoplasty with Gore-
Tex for voice restoration secondary to glottal incompetence: indications and ob-

288. Cummings CW, Purcell LL, Flint PW. Hydroxylapatite laryngeal

289. Gray SD, Barkmeier J, Jones D, et al. Vocal evaluation of thyroplas-
tic surgery in the treatment of unilateral vocal fold paralysis. Laryn-

290. Kelchner LN, Stemple JC, Gerderman E, et al. Etiology, pathophys-
iology, treatment choices, and voice results for unilateral adductor
601.

291. Chester MW, Stewart MG. Artentoid adduction combined with me-
delialization thyroplasty: An evidence-based review. Otalaryngol Head

292. Gardner GM, Altman JS, Balakrishnan G. Pediatric vocal fold me-
delialization with silastic implant: intraoperative airway management.


294. Schiratzki H, Fritzell B. Treatment of spasmodic dysphonia by means
of resection of the recurrent laryngeal nerve. Acta Otolaryngol Suppl

295. Sapir S, Aronson AE. Clinical reliability in rating voice improvement
after laryngeal nerve section for spastic dysphonia. Laryngoscope

296. Biller HF, Som ML, Lawson W. Laryngeal nerve crush for spastic

297. Dedo HH, Izdebski K. Evaluation and treatment of recurrent spas-
ticity after recurrent laryngeal nerve section. A preliminary report.

denervation-reinnervation: a new surgical treatment for adductor spasmodic

299. Truong DD, Bhidayasiri R. Botulinum toxin therapy of laryngeal
muscle hyperactivity syndromes: comparing different botulinum

300. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses

301. Sulica L. Contemporary management of spasmodic dysphonia. Curr

bilateral botulinum toxin injections for adductor spasmodic

toxin for the treatment of focal laryngeal dystonia (spastic dyspho-

study of botulinum toxin in adductor spasmodic dysphonia. Laryn-

305. Cannito MP, Woodson GE, Murry T, et al. Perceptual analyses of
spasmodic dysphonia before and after treatment. Arch Otolaryngol

306. Cummings CW, Purcell LL, Flint PW. Hydroxylapatite laryngeal

307. Watts C, Whurr R, Nye C. Botulinum toxin injections for the treat-
ment of spasmodic dysphonia. Cochrane Database of Systematic
CD004387.pub2.

308. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of
spasmodic dysphonia (laryngeal dystonia): a 12-year experience

309. Adler CH, Bansberg SF, Krein-Jones K, et al. Safety and efficacy of
botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.

310. Thomas JP, Siipuskiene N. Frozen versus fresh reconstituted botor for

311. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin


eral botulinum toxin type A (BOTOX) injections for spasmodic

314. Holzer SE, Ludlow CL. The swallowing side effects of botulinum
toxin type A injection in spasmodic dysphonia. Laryngoscope 1996;
106:86–92.

315. Woodson G, Hochstetter H, Murry T. Botulinum toxin therapy for

316. Lundy DS, Lu FL, Casiano RR, et al. The effect of patient factors on
response outcomes to Botox treatment of spasmodic dysphonia. J

317. Fisher KV, Giddens CL, Gray SD. Does botulinum toxin alter laryn-

318. Park JB, Simpson LL, Anderson TD, et al. Immunologic character-
ization of spasmodic dysphonia patients who develop resistance to

319. Ferreira LP, de Oliveira Latorre MD, Pinti Giannini SP, et al. Influen-
ce of abusive vocal habits, hydration, mastication, and sleep in the
[Epub ahead of print].

thickness of vocal folds: a possible explanation for postdialysis

321. Yiu EM, Chan RM. Effect of hydration and vocal rest on the vocal

322. Jönsdottir V, Laukkanen AM, Siikki I. Changes in teachers’ voice
quality during a working day with and without electric sound ampli-

323. Ruotsalainen JH, Sellman J, Lehto L, et al. Interventions for prevent-
ing voice disorders in adults. Cochrane Database of Systematic
CD006372.pub2.

324. Duffy OM, Hazlett DE. The impact of preventive voice care programs


326. Landes BA, McCabe BF. Dysphonia as a reaction to cigarette smoke.

327. de la Hoz RE, Shoher MT, Bienenfeld LA, et al. Vocal cord dys-
fuction in former World Trade Center (WTC) rescue and recovery

APPENDIX
Frequently Asked Questions About Voice Therapy

Why is voice therapy recommended for hoarseness? Voice therapy has been demonstrated to be effective for hoarse-
ness across the lifespan from children to older adults. A1,A2

Voice therapy is the first line of treatment for vocal fold lesions like vocal nodules, polyps, or cysts. A3,A4

These lesions often occur in people with vocally intense occupations, like teachers, attorneys, or clergymen. A5

Another pos-
sible cause of these lesions is vocal overdoing, often seen in sports enthusiasts; in socially active, aggressive, or loud children; or in high-energy adults who often speak loudly.\textsuperscript{A6-A9}

Voice therapy, specifically the Lee Silverman Voice Therapy method, has been demonstrated to be the most effective method of treating the lower volume, lower energy, and rapid-rate voice/speech of individuals with Parkinson disease.\textsuperscript{A10,A11} Voice therapy has been used to treat hoarseness concurrently with other medical therapies like botulinum toxin injections for spasmogenic dysphonia and/or tremor.\textsuperscript{A12,A13} Voice therapy has been used alone in the treatment of unilateral vocal fold paralysis\textsuperscript{A14,A15} and has been used to improve the outcome of surgical procedures as in vocal fold augmentation\textsuperscript{A16} or thyroplasty.\textsuperscript{A17} Voice therapy is an important component of any comprehensive surgical treatment for hoarseness.\textsuperscript{A18}

What happens in voice therapy? Voice therapy is a program designed to reduce hoarseness through guided change in vocal behaviors and lifestyle changes. Voice therapy consists of a variety of tasks designed to eliminate harmful vocal behavior, shape healthy vocal behavior, and assist in vocal fold wound healing after surgery or injury. Voice therapy for hoarseness generally consists of 1 to 2 therapy sessions each week for 4 to 8 weeks.\textsuperscript{A19} The duration of therapy is determined by the origin of the hoarseness and severity of the problem, co-occurring medical therapy, and importantly, patient commitment to the practice and generalization of new vocal behaviors outside the therapy session.\textsuperscript{A20}

Who provides voice therapy? Certified and licensed speech-language pathologists are healthcare professionals with the expertise needed to provide effective behavioral treatment for hoarseness.\textsuperscript{A21}

How do I find a qualified speech-language pathologist who has experience in voice? The American Speech-Language-Hearing Association (ASHA) is an excellent resource for finding a certified speech-language pathologist by going to the ASHA website (www.asha.org) or by accessing ASHA’s online search engine, called ProSearch, at: http://www.asha.org/proserv. You may also contact ASHA’s Action Center, Monday through Friday (8:30 am-5:30 pm), at: 1-800-638-8255; fax: 301-296-8580; TTY (Text Telephone Communication Device): 301-296-5650; e-mail: actioncenter@asha.org.

Does insurance cover voice therapy? Generally, Medicare, under the guidelines for coverage of speech therapy, will cover voice therapy if provided by a certified and licensed speech-language pathologist, ordered by a physician, and deemed medically necessary for the diagnosis. Medicaid varies from state to state but generally covers voice therapy, under the rules for speech therapy, up to the age of 18 years. It is best to contact your local Medicaid office, as there are state differences and program differences. Private insurance companies vary and the consumer is guided to contact his or her insurance company for specific guidelines for their purchased policies.

Are speech therapy and voice therapy the same? Speech therapy is a term that encompasses a variety of therapies, including voice therapy. Most insurance companies refer to voice therapy as speech therapy, but they are the same thing if provided by a certified and licensed speech-language pathologist.

REFERENCES